"ID";"fileName";"fileNamePE";"experiment";"tissue";"condition";"replicate";"lane";"merge";"input";"pairedEnd";"macsGroup";"phredScore";"adapter";"trimQuality";"adapterPE";"trimQualityPE"
"SRR340077";"";"";"SRP007993";"HepG2 -;- liver carcinoma -;- endoderm";"USC_ChipSeq_HepG2_TCF7L2_UCDavis";"";1;"SRX094468";NA;"false";"";"";"";"";"";""
"SRR340078";"";"";"SRP007993";"HepG2 -;- liver carcinoma -;- endoderm";"USC_ChipSeq_HepG2_TCF7L2_UCDavis";"";2;"SRX094468";NA;"false";"";"";"";"";"";""
"SRR340079";"";"";"SRP007993";"HCT-116 -;- colorectal carcinoma (PMID: 7214343) -;- endoderm";"USC_ChipSeq_HCT-116_TCF7L2_UCDavis";"";1;"SRX094469";NA;"false";"";"";"";"";"";""
"SRR340080";"";"";"SRP007993";"HCT-116 -;- colorectal carcinoma (PMID: 7214343) -;- endoderm";"USC_ChipSeq_HCT-116_TCF7L2_UCDavis";"";2;"SRX094469";NA;"false";"";"";"";"";"";""
"SRR340081";"";"";"SRP007993";"HEK293 -;- embryonic kidney. (PMID: 11967234) -;- mesoderm";"USC_ChipSeq_HEK293_TCF7L2_UCDavis";"";1;"SRX094470";NA;"false";"";"";"";"";"";""
"SRR340082";"";"";"SRP007993";"HEK293 -;- embryonic kidney. (PMID: 11967234) -;- mesoderm";"USC_ChipSeq_HEK293_TCF7L2_UCDavis";"";2;"SRX094470";NA;"false";"";"";"";"";"";""
"SRR352493";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_TCF7L2_UCDavis";"";1;"SRX100941";NA;"false";"";"";"";"";"";""
"SRR352494";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_TCF7L2_UCDavis";"";2;"SRX100941";NA;"false";"";"";"";"";"";""
"SRR352495";"";"";"SRP007993";"PANC-1 -;- pancreatic carcinoma, (PMID: 1140870) PANC-1 was established from a pancreatic carcinoma, which was extracted via pancreatico-duodenectomy specimen from a 56-year-old Caucasian individual. Malignancy of this cell line was verified via in vitro and in vivo assays. -;- endoderm";"USC_ChipSeq_PANC-1_TCF7L2_UCDavis";"";1;"SRX100942";NA;"false";"";"";"";"";"";""
"SRR352496";"";"";"SRP007993";"PANC-1 -;- pancreatic carcinoma, (PMID: 1140870) PANC-1 was established from a pancreatic carcinoma, which was extracted via pancreatico-duodenectomy specimen from a 56-year-old Caucasian individual. Malignancy of this cell line was verified via in vitro and in vivo assays. -;- endoderm";"USC_ChipSeq_PANC-1_TCF7L2_UCDavis";"";2;"SRX100942";NA;"false";"";"";"";"";"";""
"SRR352497";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_TCF7L2_UCDavis";"";1;"SRX100943";NA;"false";"";"";"";"";"";""
"SRR352498";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_TCF7L2_UCDavis";"";2;"SRX100943";NA;"false";"";"";"";"";"";""
"SRR353505";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR353506";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"USC_ChipSeq_HepG2_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR353507";"";"";"SRP007993";"HCT-116 -;- colorectal carcinoma (PMID: 7214343) -;- endoderm";"USC_ChipSeq_HCT-116_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR353665";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR361464";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_GATA3_(SC-268)_UCDavis";"";1;"SRX104409";NA;"false";"";"";"";"";"";""
"SRR361465";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_GATA3_(SC-268)_UCDavis";"";2;"SRX104409";NA;"false";"";"";"";"";"";""
"SRR501914";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_MAZ_(ab85725)_IgG-rab";"";1;"SRX150352";NA;"false";"";"";"";"";"";""
"SRR501915";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_MAZ_(ab85725)_IgG-rab";"";2;"SRX150352";NA;"false";"";"";"";"";"";""
"SRR501916";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_TNFa_NFKB_IgG-rab";"";1;"SRX150353";NA;"false";"";"";"";"";"";""
"SRR501917";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_TNFa_NFKB_IgG-rab";"";2;"SRX150353";NA;"false";"";"";"";"";"";""
"SRR501918";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_TNFa_NFKB_IgG-rab";"";3;"SRX150353";NA;"false";"";"";"";"";"";""
"SRR501919";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_CEBPZ_IgG-rab";"";1;"SRX150354";NA;"false";"";"";"";"";"";""
"SRR501920";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_CEBPZ_IgG-rab";"";2;"SRX150354";NA;"false";"";"";"";"";"";""
"SRR501921";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_ARID3A_(NB100-279)_IgG-rab";"";1;"SRX150355";NA;"false";"";"";"";"";"";""
"SRR501922";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_ARID3A_(NB100-279)_IgG-rab";"";2;"SRX150355";NA;"false";"";"";"";"";"";""
"SRR501923";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_STAT3_IgG-rab";"";1;"SRX150356";NA;"false";"";"";"";"";"";""
"SRR501924";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_STAT3_IgG-rab";"";2;"SRX150356";NA;"false";"";"";"";"";"";""
"SRR501925";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TBP_IgG-mus";"";1;"SRX150357";NA;"false";"";"";"";"";"";""
"SRR501926";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TBP_IgG-mus";"";2;"SRX150357";NA;"false";"";"";"";"";"";""
"SRR501927";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Stanford_ChipSeq_HUVEC_c-Jun_std";"";1;"SRX150358";NA;"false";"";"";"";"";"";""
"SRR501928";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Stanford_ChipSeq_HUVEC_c-Jun_std";"";2;"SRX150358";NA;"false";"";"";"";"";"";""
"SRR501929";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_TNFa_NFKB_IgG-rab";"";1;"SRX150359";NA;"false";"";"";"";"";"";""
"SRR501930";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_TNFa_NFKB_IgG-rab";"";2;"SRX150359";NA;"false";"";"";"";"";"";""
"SRR501931";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_TNFa_NFKB_IgG-rab";"";3;"SRX150359";NA;"false";"";"";"";"";"";""
"SRR501932";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_TBP_IgG-rab";"";1;"SRX150360";NA;"false";"";"";"";"";"";""
"SRR501933";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_TBP_IgG-rab";"";2;"SRX150360";NA;"false";"";"";"";"";"";""
"SRR501934";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_TNFa_NFKB_IgG-rab";"";1;"SRX150361";NA;"false";"";"";"";"";"";""
"SRR501935";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_TNFa_NFKB_IgG-rab";"";2;"SRX150361";NA;"false";"";"";"";"";"";""
"SRR501936";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_TNFa_NFKB_IgG-rab";"";3;"SRX150361";NA;"false";"";"";"";"";"";""
"SRR501937";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_TNFa_NFKB_IgG-rab";"";1;"SRX150362";NA;"false";"";"";"";"";"";""
"SRR501938";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_TNFa_NFKB_IgG-rab";"";2;"SRX150362";NA;"false";"";"";"";"";"";""
"SRR501939";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_TNFa_NFKB_IgG-rab";"";3;"SRX150362";NA;"false";"";"";"";"";"";""
"SRR501940";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_TNFa_NFKB_IgG-rab";"";4;"SRX150362";NA;"false";"";"";"";"";"";""
"SRR501941";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_TNFa_NFKB_IgG-rab";"";5;"SRX150362";NA;"false";"";"";"";"";"";""
"SRR501942";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_MAZ_(ab85725)_IgG-mus";"";1;"SRX150363";NA;"false";"";"";"";"";"";""
"SRR501943";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_MAZ_(ab85725)_IgG-mus";"";2;"SRX150363";NA;"false";"";"";"";"";"";""
"SRR501944";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_Input_IgG-mus";"";1;"SRX150364";NA;"false";"";"";"";"";"";""
"SRR501945";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_Input_IgG-mus";"";2;"SRX150364";NA;"false";"";"";"";"";"";""
"SRR501946";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_TNFa_NFKB_IgG-rab";"";1;"SRX150365";NA;"false";"";"";"";"";"";""
"SRR501947";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_TNFa_NFKB_IgG-rab";"";2;"SRX150365";NA;"false";"";"";"";"";"";""
"SRR501948";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_TNFa_NFKB_IgG-rab";"";3;"SRX150365";NA;"false";"";"";"";"";"";""
"SRR501949";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_Input_IgG-mus";"";1;"SRX150366";NA;"false";"";"";"";"";"";""
"SRR501950";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_Input_IgG-mus";"";2;"SRX150366";NA;"false";"";"";"";"";"";""
"SRR501951";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_Pol2_IgG-mus";"";1;"SRX150367";NA;"false";"";"";"";"";"";""
"SRR501952";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_Pol2_IgG-mus";"";2;"SRX150367";NA;"false";"";"";"";"";"";""
"SRR501953";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_Pol2_IgG-mus";"";3;"SRX150367";NA;"false";"";"";"";"";"";""
"SRR501954";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_Pol2_IgG-mus";"";4;"SRX150367";NA;"false";"";"";"";"";"";""
"SRR501955";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_Pol2_IgG-mus";"";5;"SRX150367";NA;"false";"";"";"";"";"";""
"SRR501956";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_Pol2_IgG-mus";"";6;"SRX150367";NA;"false";"";"";"";"";"";""
"SRR501957";"";"";"SRP007993";"U2OS -;- osteosarcoma from the tibia of a 15 year old, J. Ponten and E. Saksela derived this line (originally 2T) in 1964 from a moderately differentiated sarcoma, viruses were not detected during co-cultivation with WI-38 cells or in CF tests against SV40, RSV or adenoviruses, mycoplasma contamination was detected and eliminated in 1972, (PMID: 6081590) -;- mesoderm";"USC_ChipSeq_U2OS_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR501958";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_SIN3A_(NB600-1263)_IgG-rab";"";1;"SRX150369";NA;"false";"";"";"";"";"";""
"SRR501959";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_SIN3A_(NB600-1263)_IgG-rab";"";2;"SRX150369";NA;"false";"";"";"";"";"";""
"SRR501960";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_MafK_(ab50322)_IgG-rab";"";1;"SRX150370";NA;"false";"";"";"";"";"";""
"SRR501961";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_MafK_(ab50322)_IgG-rab";"";2;"SRX150370";NA;"false";"";"";"";"";"";""
"SRR501962";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_Pol2_IgG-mus";"";1;"SRX150371";NA;"false";"";"";"";"";"";""
"SRR501963";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_Pol2_IgG-mus";"";2;"SRX150371";NA;"false";"";"";"";"";"";""
"SRR501964";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_Pol2_IgG-mus";"";3;"SRX150371";NA;"false";"";"";"";"";"";""
"SRR501965";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_MafK_(ab50322)_IgG-rab";"";1;"SRX150372";NA;"false";"";"";"";"";"";""
"SRR501966";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_MafK_(ab50322)_IgG-rab";"";2;"SRX150372";NA;"false";"";"";"";"";"";""
"SRR501967";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Mxi1_(AF4185)_IgG-rab";"";1;"SRX150373";NA;"false";"";"";"";"";"";""
"SRR501968";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Mxi1_(AF4185)_IgG-rab";"";2;"SRX150373";NA;"false";"";"";"";"";"";""
"SRR501969";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_p300_IgG-mus";"";1;"SRX150374";NA;"false";"";"";"";"";"";""
"SRR501970";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_p300_IgG-mus";"";2;"SRX150374";NA;"false";"";"";"";"";"";""
"SRR501971";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_CEBPB_IgG-rab";"";1;"SRX150375";NA;"false";"";"";"";"";"";""
"SRR501972";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_CEBPB_IgG-rab";"";2;"SRX150375";NA;"false";"";"";"";"";"";""
"SRR501973";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_CHD1_(A301-218A)_IgG-rab";"";1;"SRX150376";NA;"false";"";"";"";"";"";""
"SRR501974";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_CHD1_(A301-218A)_IgG-rab";"";2;"SRX150376";NA;"false";"";"";"";"";"";""
"SRR501975";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_CHD2_(AB68301)_IgG-rab";"";1;"SRX150377";NA;"false";"";"";"";"";"";""
"SRR501976";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_CHD2_(AB68301)_IgG-rab";"";2;"SRX150377";NA;"false";"";"";"";"";"";""
"SRR501977";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_Max_IgG-rab";"";1;"SRX150378";NA;"false";"";"";"";"";"";""
"SRR501978";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_Max_IgG-rab";"";2;"SRX150378";NA;"false";"";"";"";"";"";""
"SRR501979";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_Pol2(phosphoS2)_IgG-rab";"";1;"SRX150379";NA;"false";"";"";"";"";"";""
"SRR501980";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_Pol2(phosphoS2)_IgG-rab";"";2;"SRX150379";NA;"false";"";"";"";"";"";""
"SRR501981";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_Rad21_IgG-rab";"";1;"SRX150380";NA;"false";"";"";"";"";"";""
"SRR501982";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_Rad21_IgG-rab";"";2;"SRX150380";NA;"false";"";"";"";"";"";""
"SRR501983";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_CHD1_(A301-218A)_IgG-mus";"";1;"SRX150381";NA;"false";"";"";"";"";"";""
"SRR501984";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_CHD1_(A301-218A)_IgG-mus";"";2;"SRX150381";NA;"false";"";"";"";"";"";""
"SRR501985";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_GCN5_std";"";1;"SRX150382";NA;"false";"";"";"";"";"";""
"SRR501986";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_GCN5_std";"";2;"SRX150382";NA;"false";"";"";"";"";"";""
"SRR501987";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_TBP_IgG-rab";"";1;"SRX150383";NA;"false";"";"";"";"";"";""
"SRR501988";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_TBP_IgG-rab";"";2;"SRX150383";NA;"false";"";"";"";"";"";""
"SRR501989";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_RFX5_(200-401-194)_IgG-rab";"";1;"SRX150384";NA;"false";"";"";"";"";"";""
"SRR501990";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_RFX5_(200-401-194)_IgG-rab";"";2;"SRX150384";NA;"false";"";"";"";"";"";""
"SRR501991";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_MafK_(ab50322)_IgG-rab";"";1;"SRX150385";NA;"false";"";"";"";"";"";""
"SRR501992";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_MafK_(ab50322)_IgG-rab";"";2;"SRX150385";NA;"false";"";"";"";"";"";""
"SRR501993";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_MafF_(M8194)_IgG-rab";"";1;"SRX150386";NA;"false";"";"";"";"";"";""
"SRR501994";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_MafF_(M8194)_IgG-rab";"";2;"SRX150386";NA;"false";"";"";"";"";"";""
"SRR501995";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_CHD2_(AB68301)_IgG-rab";"";1;"SRX150387";NA;"false";"";"";"";"";"";""
"SRR501996";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_CHD2_(AB68301)_IgG-rab";"";2;"SRX150387";NA;"false";"";"";"";"";"";""
"SRR501997";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Nrf1_IgG-rab";"";1;"SRX150388";NA;"false";"";"";"";"";"";""
"SRR501998";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Nrf1_IgG-rab";"";2;"SRX150388";NA;"false";"";"";"";"";"";""
"SRR501999";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Nrf1_IgG-mus";"";1;"SRX150389";NA;"false";"";"";"";"";"";""
"SRR502000";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Nrf1_IgG-mus";"";2;"SRX150389";NA;"false";"";"";"";"";"";""
"SRR502001";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_SMC3_(ab9263)_IgG-rab";"";1;"SRX150390";NA;"false";"";"";"";"";"";""
"SRR502002";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_SMC3_(ab9263)_IgG-rab";"";2;"SRX150390";NA;"false";"";"";"";"";"";""
"SRR502003";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_MafK_(ab50322)_IgG-rab";"";1;"SRX150391";NA;"false";"";"";"";"";"";""
"SRR502004";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_MafK_(ab50322)_IgG-rab";"";2;"SRX150391";NA;"false";"";"";"";"";"";""
"SRR502005";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_Pol2_std";"";1;"SRX150392";NA;"false";"";"";"";"";"";""
"SRR502006";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_Pol2_std";"";2;"SRX150392";NA;"false";"";"";"";"";"";""
"SRR502007";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_Pol2_std";"";3;"SRX150392";NA;"false";"";"";"";"";"";""
"SRR502008";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_Input_std";"";1;"SRX150393";NA;"false";"";"";"";"";"";""
"SRR502009";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_Input_std";"";2;"SRX150393";NA;"false";"";"";"";"";"";""
"SRR502010";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_Input_std";"";3;"SRX150393";NA;"false";"";"";"";"";"";""
"SRR502011";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_SREBP2_std";"";1;"SRX150394";NA;"false";"";"";"";"";"";""
"SRR502012";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_SREBP2_std";"";2;"SRX150394";NA;"false";"";"";"";"";"";""
"SRR502013";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_SREBP2_std";"";3;"SRX150394";NA;"false";"";"";"";"";"";""
"SRR502014";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_SREBP1_std";"";1;"SRX150395";NA;"false";"";"";"";"";"";""
"SRR502015";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_SREBP1_std";"";2;"SRX150395";NA;"false";"";"";"";"";"";""
"SRR502016";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Yale_ChipSeq_HepG2_pravastatin_SREBP1_std";"";3;"SRX150395";NA;"false";"";"";"";"";"";""
"SRR502017";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Yale_ChipSeq_GM12878_Pol3_std";"";1;"SRX150396";NA;"false";"";"";"";"";"";""
"SRR502018";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Yale_ChipSeq_GM12878_Pol3_std";"";2;"SRX150396";NA;"false";"";"";"";"";"";""
"SRR502019";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_c-Fos_std";"";1;"SRX150397";NA;"false";"";"";"";"";"";""
"SRR502020";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_c-Fos_std";"";2;"SRX150397";NA;"false";"";"";"";"";"";""
"SRR502021";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Max_std";"";1;"SRX150398";NA;"false";"";"";"";"";"";""
"SRR502022";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Max_std";"";2;"SRX150398";NA;"false";"";"";"";"";"";""
"SRR502023";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_Rad21_std";"";1;"SRX150399";NA;"false";"";"";"";"";"";""
"SRR502024";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_Rad21_std";"";2;"SRX150399";NA;"false";"";"";"";"";"";""
"SRR502025";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_c-Myc_std";"";1;"SRX150400";NA;"false";"";"";"";"";"";""
"SRR502026";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_c-Myc_std";"";2;"SRX150400";NA;"false";"";"";"";"";"";""
"SRR502027";"";"";"SRP007993";"SH-SY5Y -;- neuroblastoma clonal subline of the neuroepithelioma cell line SK-N-SH from the 1970 bone marrow biopsy of a 4-year-old girl with metastatic neuroblastoma, trisomy of 1q -;- ectoderm";"USC_ChipSeq_SH-SY5Y_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502028";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_Input_IgG-mus";"";1;"SRX150402";NA;"false";"";"";"";"";"";""
"SRR502029";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_Input_IgG-mus";"";2;"SRX150402";NA;"false";"";"";"";"";"";""
"SRR502030";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_Pol2_IgG-mus";"";1;"SRX150403";NA;"false";"";"";"";"";"";""
"SRR502031";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_Pol2_IgG-mus";"";2;"SRX150403";NA;"false";"";"";"";"";"";""
"SRR502032";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_Pol2_IgG-mus";"";3;"SRX150403";NA;"false";"";"";"";"";"";""
"SRR502033";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_Input_IgG-mus";"";1;"SRX150404";NA;"false";"";"";"";"";"";""
"SRR502034";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_Input_IgG-mus";"";2;"SRX150404";NA;"false";"";"";"";"";"";""
"SRR502035";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_Pol2_IgG-mus";"";1;"SRX150405";NA;"false";"";"";"";"";"";""
"SRR502036";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_Pol2_IgG-mus";"";2;"SRX150405";NA;"false";"";"";"";"";"";""
"SRR502037";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_Pol2_IgG-mus";"";3;"SRX150405";NA;"false";"";"";"";"";"";""
"SRR502038";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_Pol2_IgG-mus";"";4;"SRX150405";NA;"false";"";"";"";"";"";""
"SRR502039";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_ELK1_(1277-1)_IgG-rab";"";1;"SRX150406";NA;"false";"";"";"";"";"";""
"SRR502040";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_ELK1_(1277-1)_IgG-rab";"";2;"SRX150406";NA;"false";"";"";"";"";"";""
"SRR502041";"";"";"SRP007993";"HEK293-T-REx -;- embryonic kidney cells transformed with Adenovirus 5 DNA stably expressing tetracycline repressor, HEK293 (ATCC number CRL-1573) is the parental cell line, hypotriploid, XXX -;- mesoderm";"USC_ChipSeq_HEK293-T-REx_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502042";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_JunD_IgG-rab";"";1;"SRX150408";NA;"false";"";"";"";"";"";""
"SRR502043";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_JunD_IgG-rab";"";2;"SRX150408";NA;"false";"";"";"";"";"";""
"SRR502129";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_GATA-2_UCDavis";"";1;"SRX150453";NA;"false";"";"";"";"";"";""
"SRR502130";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_GATA-2_UCDavis";"";2;"SRX150453";NA;"false";"";"";"";"";"";""
"SRR502044";"";"";"SRP007993";"GM08714 -;- lymphoblastoid cell line, Instability of heterochromatin of chromosomes 1, 9, and 16 with variable combined immunodeficiency; dysmorphic facial features, developmental delay, malabsorption, and recurrent infections; see GM08747 Fibroblast; donor subject is a compound heterozygote: one allele has a G>A transition at nucleotide 1807 (1807G>A) of the DNMT3B gene resulting in an Ala to Thr substitution at codon 603 [Ala603Thr (A603T)], the mutation occurring in a region between motifs I and IV within the catalytic domain of DNMT3B; the second allele has a G>A transition within intron 22 located 11 nucleotides 5-prime of the normal splice acceptor site [IVS22AS,G>A,-11] resulting in the generation of a novel splice acceptor site and a 9-bp insertion in the processed RNA. This results in the insertion of 3 amino acids (serine, threonine, and proline) at codon 744 (744ins3). The insertion was within the conserved region of the catalytic domain, which is likely to be disrupted by the insertion of a proline residue. This mutation was de novo. -;- mesoderm";"USC_ChipSeq_GM08714_ZNF274_UCDavis";"";1;"SRX150409";NA;"false";"";"";"";"";"";""
"SRR502045";"";"";"SRP007993";"GM08714 -;- lymphoblastoid cell line, Instability of heterochromatin of chromosomes 1, 9, and 16 with variable combined immunodeficiency; dysmorphic facial features, developmental delay, malabsorption, and recurrent infections; see GM08747 Fibroblast; donor subject is a compound heterozygote: one allele has a G>A transition at nucleotide 1807 (1807G>A) of the DNMT3B gene resulting in an Ala to Thr substitution at codon 603 [Ala603Thr (A603T)], the mutation occurring in a region between motifs I and IV within the catalytic domain of DNMT3B; the second allele has a G>A transition within intron 22 located 11 nucleotides 5-prime of the normal splice acceptor site [IVS22AS,G>A,-11] resulting in the generation of a novel splice acceptor site and a 9-bp insertion in the processed RNA. This results in the insertion of 3 amino acids (serine, threonine, and proline) at codon 744 (744ins3). The insertion was within the conserved region of the catalytic domain, which is likely to be disrupted by the insertion of a proline residue. This mutation was de novo. -;- mesoderm";"USC_ChipSeq_GM08714_ZNF274_UCDavis";"";2;"SRX150409";NA;"false";"";"";"";"";"";""
"SRR502046";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_E2F4_IgG-mus";"";1;"SRX150410";NA;"false";"";"";"";"";"";""
"SRR502047";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_E2F4_IgG-mus";"";2;"SRX150410";NA;"false";"";"";"";"";"";""
"SRR502048";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_SIN3A_(NB600-1263)_IgG-mus";"";1;"SRX150411";NA;"false";"";"";"";"";"";""
"SRR502049";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_SIN3A_(NB600-1263)_IgG-mus";"";2;"SRX150411";NA;"false";"";"";"";"";"";""
"SRR502050";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Rad21_IgG-rab";"";1;"SRX150412";NA;"false";"";"";"";"";"";""
"SRR502051";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Rad21_IgG-rab";"";2;"SRX150412";NA;"false";"";"";"";"";"";""
"SRR502052";"";"";"SRP007993";"PBDEFetal -;- peripheral blood-derived erythroblasts from 16-19 week human fetal liver -;- mesoderm";"USC_ChipSeq_PBDEFetal_GATA-1_UCDavis";"";1;"SRX150413";NA;"false";"";"";"";"";"";""
"SRR502053";"";"";"SRP007993";"PBDEFetal -;- peripheral blood-derived erythroblasts from 16-19 week human fetal liver -;- mesoderm";"USC_ChipSeq_PBDEFetal_GATA-1_UCDavis";"";2;"SRX150413";NA;"false";"";"";"";"";"";""
"SRR502054";"";"";"SRP007993";"PBDEFetal -;- peripheral blood-derived erythroblasts from 16-19 week human fetal liver -;- mesoderm";"USC_ChipSeq_PBDEFetal_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502055";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_MAZ_(ab85725)_IgG-rab";"";1;"SRX150415";NA;"false";"";"";"";"";"";""
"SRR502056";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_MAZ_(ab85725)_IgG-rab";"";2;"SRX150415";NA;"false";"";"";"";"";"";""
"SRR502057";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ARID3A_(sc-8821)_IgG-rab";"";1;"SRX150416";NA;"false";"";"";"";"";"";""
"SRR502058";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ARID3A_(sc-8821)_IgG-rab";"";2;"SRX150416";NA;"false";"";"";"";"";"";""
"SRR502059";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_MAZ_(ab85725)_IgG-rab";"";1;"SRX150417";NA;"false";"";"";"";"";"";""
"SRR502060";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_MAZ_(ab85725)_IgG-rab";"";2;"SRX150417";NA;"false";"";"";"";"";"";""
"SRR502061";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_UBF_(sc-13125)_IgG-mus";"";1;"SRX150418";NA;"false";"";"";"";"";"";""
"SRR502062";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_UBF_(sc-13125)_IgG-mus";"";2;"SRX150418";NA;"false";"";"";"";"";"";""
"SRR502063";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Input_IgG-rab";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502064";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_ATF1_(06-325)_std";"";1;"SRX150420";NA;"false";"";"";"";"";"";""
"SRR502065";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_ATF1_(06-325)_std";"";2;"SRX150420";NA;"false";"";"";"";"";"";""
"SRR502066";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_c-Jun_IgG-rab";"";1;"SRX150421";NA;"false";"";"";"";"";"";""
"SRR502067";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_c-Jun_IgG-rab";"";2;"SRX150421";NA;"false";"";"";"";"";"";""
"SRR502068";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_TFIIIC-110_std";"";1;"SRX150422";NA;"false";"";"";"";"";"";""
"SRR502069";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_TFIIIC-110_std";"";2;"SRX150422";NA;"false";"";"";"";"";"";""
"SRR502070";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_TFIIIC-110_std";"";1;"SRX150423";NA;"false";"";"";"";"";"";""
"SRR502071";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_TFIIIC-110_std";"";2;"SRX150423";NA;"false";"";"";"";"";"";""
"SRR502072";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_TFIIIC-110_std";"";3;"SRX150423";NA;"false";"";"";"";"";"";""
"SRR502073";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Max_IgG-rab";"";1;"SRX150424";NA;"false";"";"";"";"";"";""
"SRR502074";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Max_IgG-rab";"";2;"SRX150424";NA;"false";"";"";"";"";"";""
"SRR502075";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_ELK1_(1277-1)_IgG-mus";"";1;"SRX150425";NA;"false";"";"";"";"";"";""
"SRR502076";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_ELK1_(1277-1)_IgG-mus";"";2;"SRX150425";NA;"false";"";"";"";"";"";""
"SRR502077";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"USC_ChipSeq_HUVEC_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502078";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"USC_ChipSeq_HUVEC_GATA-2_UCDavis";"";1;"SRX150427";NA;"false";"";"";"";"";"";""
"SRR502079";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"USC_ChipSeq_HUVEC_GATA-2_UCDavis";"";2;"SRX150427";NA;"false";"";"";"";"";"";""
"SRR502080";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_Max_UCDavis";"";1;"SRX150428";NA;"false";"";"";"";"";"";""
"SRR502081";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_Max_UCDavis";"";2;"SRX150428";NA;"false";"";"";"";"";"";""
"SRR502082";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"USC_ChipSeq_GM12878_ZNF274_std";"";1;"SRX150429";NA;"false";"";"";"";"";"";""
"SRR502083";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"USC_ChipSeq_GM12878_ZNF274_std";"";2;"SRX150429";NA;"false";"";"";"";"";"";""
"SRR502084";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"USC_ChipSeq_HepG2_ZNF274_UCDavis";"";1;"SRX150430";NA;"false";"";"";"";"";"";""
"SRR502085";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"USC_ChipSeq_HepG2_ZNF274_UCDavis";"";2;"SRX150430";NA;"false";"";"";"";"";"";""
"SRR502086";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_ELK4_UCDavis";"";1;"SRX150431";NA;"false";"";"";"";"";"";""
"SRR502087";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_ELK4_UCDavis";"";2;"SRX150431";NA;"false";"";"";"";"";"";""
"SRR502088";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_SUZ12_UCDavis";"";1;"SRX150432";NA;"false";"";"";"";"";"";""
"SRR502089";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_SUZ12_UCDavis";"";2;"SRX150432";NA;"false";"";"";"";"";"";""
"SRR502090";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502091";"";"";"SRP007993";"NB4 -;- acute promyelocytic leukemia cell line. (PMID: 1995093) -;- mesoderm";"Yale_ChipSeq_NB4_Pol2_std";"";1;"SRX150434";NA;"false";"";"";"";"";"";""
"SRR502092";"";"";"SRP007993";"NB4 -;- acute promyelocytic leukemia cell line. (PMID: 1995093) -;- mesoderm";"Yale_ChipSeq_NB4_Pol2_std";"";2;"SRX150434";NA;"false";"";"";"";"";"";""
"SRR502093";"";"";"SRP007993";"NB4 -;- acute promyelocytic leukemia cell line. (PMID: 1995093) -;- mesoderm";"Yale_ChipSeq_NB4_Pol2_std";"";3;"SRX150434";NA;"false";"";"";"";"";"";""
"SRR502094";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_c-Fos_std";"";1;"SRX150435";NA;"false";"";"";"";"";"";""
"SRR502095";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_c-Fos_std";"";2;"SRX150435";NA;"false";"";"";"";"";"";""
"SRR502096";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_c-Fos_std";"";3;"SRX150435";NA;"false";"";"";"";"";"";""
"SRR502097";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_USF2_IgG-rab";"";1;"SRX150436";NA;"false";"";"";"";"";"";""
"SRR502098";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_USF2_IgG-rab";"";2;"SRX150436";NA;"false";"";"";"";"";"";""
"SRR502099";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_IFNg30_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502100";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_Pol2_std";"";1;"SRX150438";NA;"false";"";"";"";"";"";""
"SRR502101";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_Pol2_std";"";2;"SRX150438";NA;"false";"";"";"";"";"";""
"SRR502102";"";"";"SRP007993";"NB4 -;- acute promyelocytic leukemia cell line. (PMID: 1995093) -;- mesoderm";"Yale_ChipSeq_NB4_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502103";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_IFNg30_STAT1_std";"";1;"SRX150440";NA;"false";"";"";"";"";"";""
"SRR502104";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_IFNg30_STAT1_std";"";2;"SRX150440";NA;"false";"";"";"";"";"";""
"SRR502105";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Nrf1_IgG-rab";"";1;"SRX150441";NA;"false";"";"";"";"";"";""
"SRR502106";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Nrf1_IgG-rab";"";2;"SRX150441";NA;"false";"";"";"";"";"";""
"SRR502107";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_ZKSCAN1_(HPA006672)_IgG-rab";"";1;"SRX150442";NA;"false";"";"";"";"";"";""
"SRR502108";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_ZKSCAN1_(HPA006672)_IgG-rab";"";2;"SRX150442";NA;"false";"";"";"";"";"";""
"SRR502109";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_Input_std";"";1;"SRX150443";NA;"false";"";"";"";"";"";""
"SRR502110";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_Input_std";"";2;"SRX150443";NA;"false";"";"";"";"";"";""
"SRR502111";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_c-Jun_IgG-rab";"";1;"SRX150444";NA;"false";"";"";"";"";"";""
"SRR502112";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_c-Jun_IgG-rab";"";2;"SRX150444";NA;"false";"";"";"";"";"";""
"SRR502113";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_E2F4_std";"";1;"SRX150445";NA;"false";"";"";"";"";"";""
"SRR502114";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_E2F4_std";"";2;"SRX150445";NA;"false";"";"";"";"";"";""
"SRR502115";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_HA-E2F1_std";"";1;"SRX150446";NA;"false";"";"";"";"";"";""
"SRR502116";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_HA-E2F1_std";"";2;"SRX150446";NA;"false";"";"";"";"";"";""
"SRR502117";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_AP-2alpha_std";"";1;"SRX150447";NA;"false";"";"";"";"";"";""
"SRR502118";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_AP-2alpha_std";"";2;"SRX150447";NA;"false";"";"";"";"";"";""
"SRR502119";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_YY1_UCDavis";"";1;"SRX150448";NA;"false";"";"";"";"";"";""
"SRR502120";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_YY1_UCDavis";"";2;"SRX150448";NA;"false";"";"";"";"";"";""
"SRR502121";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_TR4_std";"";1;"SRX150449";NA;"false";"";"";"";"";"";""
"SRR502122";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_TR4_std";"";2;"SRX150449";NA;"false";"";"";"";"";"";""
"SRR502123";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_AP-2gamma_std";"";1;"SRX150450";NA;"false";"";"";"";"";"";""
"SRR502124";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_AP-2gamma_std";"";2;"SRX150450";NA;"false";"";"";"";"";"";""
"SRR502125";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_SIRT6_std";"";1;"SRX150451";NA;"false";"";"";"";"";"";""
"SRR502126";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_SIRT6_std";"";2;"SRX150451";NA;"false";"";"";"";"";"";""
"SRR502127";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_RPC155_std";"";1;"SRX150452";NA;"false";"";"";"";"";"";""
"SRR502128";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_RPC155_std";"";2;"SRX150452";NA;"false";"";"";"";"";"";""
"SRR502131";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_TR4_UCDavis";"";1;"SRX150454";NA;"false";"";"";"";"";"";""
"SRR502132";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_TR4_UCDavis";"";2;"SRX150454";NA;"false";"";"";"";"";"";""
"SRR502133";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_EBF1_(SC-137065)_std";"";1;"SRX150455";NA;"false";"";"";"";"";"";""
"SRR502134";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_EBF1_(SC-137065)_std";"";2;"SRX150455";NA;"false";"";"";"";"";"";""
"SRR502135";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_SMC3_(ab9263)_IgG-mus";"";1;"SRX150456";NA;"false";"";"";"";"";"";""
"SRR502136";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_SMC3_(ab9263)_IgG-mus";"";2;"SRX150456";NA;"false";"";"";"";"";"";""
"SRR502137";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_BRCA1_(A300-000A)_IgG-mus";"";1;"SRX150457";NA;"false";"";"";"";"";"";""
"SRR502138";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_BRCA1_(A300-000A)_IgG-mus";"";2;"SRX150457";NA;"false";"";"";"";"";"";""
"SRR502139";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_CHD2_(AB68301)_IgG-mus";"";1;"SRX150458";NA;"false";"";"";"";"";"";""
"SRR502140";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_CHD2_(AB68301)_IgG-mus";"";2;"SRX150458";NA;"false";"";"";"";"";"";""
"SRR502141";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Rad21_IgG-rab";"";1;"SRX150459";NA;"false";"";"";"";"";"";""
"SRR502142";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Rad21_IgG-rab";"";2;"SRX150459";NA;"false";"";"";"";"";"";""
"SRR502143";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_USF2_IgG-rab";"";1;"SRX150460";NA;"false";"";"";"";"";"";""
"SRR502144";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_USF2_IgG-rab";"";2;"SRX150460";NA;"false";"";"";"";"";"";""
"SRR502145";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Input_IgG-rab";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502146";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_RFX5_(200-401-194)_IgG-rab";"";1;"SRX150462";NA;"false";"";"";"";"";"";""
"SRR502147";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_RFX5_(200-401-194)_IgG-rab";"";2;"SRX150462";NA;"false";"";"";"";"";"";""
"SRR502148";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Pol2(phosphoS2)_IgG-rab";"";1;"SRX150463";NA;"false";"";"";"";"";"";""
"SRR502149";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Pol2(phosphoS2)_IgG-rab";"";2;"SRX150463";NA;"false";"";"";"";"";"";""
"SRR502150";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_SMC3_(ab9263)_IgG-rab";"";1;"SRX150464";NA;"false";"";"";"";"";"";""
"SRR502151";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_SMC3_(ab9263)_IgG-rab";"";2;"SRX150464";NA;"false";"";"";"";"";"";""
"SRR502152";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_COREST_(ab24166)_IgG-rab";"";1;"SRX150465";NA;"false";"";"";"";"";"";""
"SRR502153";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_COREST_(ab24166)_IgG-rab";"";2;"SRX150465";NA;"false";"";"";"";"";"";""
"SRR502154";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_COREST_(ab24166)_IgG-rab";"";3;"SRX150465";NA;"false";"";"";"";"";"";""
"SRR502155";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2_IgG-mus";"";1;"SRX150466";NA;"false";"";"";"";"";"";""
"SRR502156";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2_IgG-mus";"";2;"SRX150466";NA;"false";"";"";"";"";"";""
"SRR502157";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2_IgG-mus";"";3;"SRX150466";NA;"false";"";"";"";"";"";""
"SRR502158";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2_IgG-mus";"";4;"SRX150466";NA;"false";"";"";"";"";"";""
"SRR502159";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2_IgG-mus";"";5;"SRX150466";NA;"false";"";"";"";"";"";""
"SRR502160";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2_IgG-mus";"";6;"SRX150466";NA;"false";"";"";"";"";"";""
"SRR502161";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2_IgG-mus";"";7;"SRX150466";NA;"false";"";"";"";"";"";""
"SRR502162";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_Input_IgG-mus";"";1;"SRX150467";NA;"false";"";"";"";"";"";""
"SRR502163";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_Input_IgG-mus";"";2;"SRX150467";NA;"false";"";"";"";"";"";""
"SRR502164";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg30_Pol2_std";"";1;"SRX150468";NA;"false";"";"";"";"";"";""
"SRR502165";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg30_Pol2_std";"";2;"SRX150468";NA;"false";"";"";"";"";"";""
"SRR502166";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_Pol2_IgG-mus";"";1;"SRX150469";NA;"false";"";"";"";"";"";""
"SRR502167";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_Pol2_IgG-mus";"";2;"SRX150469";NA;"false";"";"";"";"";"";""
"SRR502168";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Input_IgG-mus";"";1;"SRX150470";NA;"false";"";"";"";"";"";""
"SRR502169";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Input_IgG-mus";"";2;"SRX150470";NA;"false";"";"";"";"";"";""
"SRR502170";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_ATF3_std";"";1;"SRX150471";NA;"false";"";"";"";"";"";""
"SRR502171";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_ATF3_std";"";2;"SRX150471";NA;"false";"";"";"";"";"";""
"SRR502172";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_NELFe_std";"";1;"SRX150472";NA;"false";"";"";"";"";"";""
"SRR502173";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_NELFe_std";"";2;"SRX150472";NA;"false";"";"";"";"";"";""
"SRR502174";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Stanford_ChipSeq_HUVEC_Pol2_std";"";1;"SRX150473";NA;"false";"";"";"";"";"";""
"SRR502175";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Stanford_ChipSeq_HUVEC_Pol2_std";"";2;"SRX150473";NA;"false";"";"";"";"";"";""
"SRR502176";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Stanford_ChipSeq_HUVEC_Pol2_std";"";3;"SRX150473";NA;"false";"";"";"";"";"";""
"SRR502177";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_GTF2B_std";"";1;"SRX150474";NA;"false";"";"";"";"";"";""
"SRR502178";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_GTF2B_std";"";2;"SRX150474";NA;"false";"";"";"";"";"";""
"SRR502179";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Pol2_std";"";1;"SRX150475";NA;"false";"";"";"";"";"";""
"SRR502180";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Pol2_std";"";2;"SRX150475";NA;"false";"";"";"";"";"";""
"SRR502181";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Pol2_std";"";3;"SRX150475";NA;"false";"";"";"";"";"";""
"SRR502182";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_36hr_c-Fos_Harvard_Control";"";1;"SRX150476";NA;"false";"";"";"";"";"";""
"SRR502183";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_36hr_c-Fos_Harvard_Control";"";2;"SRX150476";NA;"false";"";"";"";"";"";""
"SRR502184";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_4hr_c-Fos_Harvard_Control";"";1;"SRX150477";NA;"false";"";"";"";"";"";""
"SRR502185";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_4hr_c-Fos_Harvard_Control";"";2;"SRX150477";NA;"false";"";"";"";"";"";""
"SRR502186";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_12hr_c-Fos_Harvard_Control";"";1;"SRX150478";NA;"false";"";"";"";"";"";""
"SRR502187";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_12hr_c-Fos_Harvard_Control";"";2;"SRX150478";NA;"false";"";"";"";"";"";""
"SRR502188";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_12hr_STAT3_Harvard_Control";"";1;"SRX150479";NA;"false";"";"";"";"";"";""
"SRR502189";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_12hr_STAT3_Harvard_Control";"";2;"SRX150479";NA;"false";"";"";"";"";"";""
"SRR502190";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_36hr_E2F4_Harvard_Control";"";1;"SRX150480";NA;"false";"";"";"";"";"";""
"SRR502191";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_36hr_E2F4_Harvard_Control";"";2;"SRX150480";NA;"false";"";"";"";"";"";""
"SRR502192";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_p300_IgG-rab";"";1;"SRX150481";NA;"false";"";"";"";"";"";""
"SRR502193";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_p300_IgG-rab";"";2;"SRX150481";NA;"false";"";"";"";"";"";""
"SRR502194";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Pol2(phosphoS2)_IgG-rab";"";1;"SRX150482";NA;"false";"";"";"";"";"";""
"SRR502195";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Pol2(phosphoS2)_IgG-rab";"";2;"SRX150482";NA;"false";"";"";"";"";"";""
"SRR502196";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_MafK_(ab50322)_IgG-rab";"";1;"SRX150483";NA;"false";"";"";"";"";"";""
"SRR502197";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_MafK_(ab50322)_IgG-rab";"";2;"SRX150483";NA;"false";"";"";"";"";"";""
"SRR502198";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_CTCF_(SC-15914)_IgG-rab";"";1;"SRX150484";NA;"false";"";"";"";"";"";""
"SRR502199";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_CTCF_(SC-15914)_IgG-rab";"";2;"SRX150484";NA;"false";"";"";"";"";"";""
"SRR502200";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Max_IgG-rab";"";1;"SRX150485";NA;"false";"";"";"";"";"";""
"SRR502201";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Max_IgG-rab";"";2;"SRX150485";NA;"false";"";"";"";"";"";""
"SRR502202";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Max_IgG-rab";"";1;"SRX150486";NA;"false";"";"";"";"";"";""
"SRR502203";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Max_IgG-rab";"";2;"SRX150486";NA;"false";"";"";"";"";"";""
"SRR502204";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_CTCF_(SC-15914)_IgG-rab";"";1;"SRX150487";NA;"false";"";"";"";"";"";""
"SRR502205";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_CTCF_(SC-15914)_IgG-rab";"";2;"SRX150487";NA;"false";"";"";"";"";"";""
"SRR502206";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_NF-YB_IgG-rab";"";1;"SRX150488";NA;"false";"";"";"";"";"";""
"SRR502207";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_NF-YB_IgG-rab";"";2;"SRX150488";NA;"false";"";"";"";"";"";""
"SRR502208";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Yale_ChipSeq_GM12878_c-Fos_std";"";1;"SRX150489";NA;"false";"";"";"";"";"";""
"SRR502209";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Yale_ChipSeq_GM12878_c-Fos_std";"";2;"SRX150489";NA;"false";"";"";"";"";"";""
"SRR502210";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Yale_ChipSeq_GM12878_c-Fos_std";"";3;"SRX150489";NA;"false";"";"";"";"";"";""
"SRR502211";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_c-Myc_std";"";1;"SRX150490";NA;"false";"";"";"";"";"";""
"SRR502212";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_c-Myc_std";"";2;"SRX150490";NA;"false";"";"";"";"";"";""
"SRR502213";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_c-Jun_std";"";1;"SRX150491";NA;"false";"";"";"";"";"";""
"SRR502214";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_c-Jun_std";"";2;"SRX150491";NA;"false";"";"";"";"";"";""
"SRR502215";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Yale_ChipSeq_GM12878_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502216";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_NF-E2_std";"";1;"SRX150493";NA;"false";"";"";"";"";"";""
"SRR502217";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_NF-E2_std";"";2;"SRX150493";NA;"false";"";"";"";"";"";""
"SRR502218";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_GCN5_std";"";1;"SRX150494";NA;"false";"";"";"";"";"";""
"SRR502219";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_GCN5_std";"";2;"SRX150494";NA;"false";"";"";"";"";"";""
"SRR502220";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_ZZZ3_std";"";1;"SRX150495";NA;"false";"";"";"";"";"";""
"SRR502221";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_ZZZ3_std";"";2;"SRX150495";NA;"false";"";"";"";"";"";""
"SRR502222";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_SPT20_std";"";1;"SRX150496";NA;"false";"";"";"";"";"";""
"SRR502223";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_SPT20_std";"";2;"SRX150496";NA;"false";"";"";"";"";"";""
"SRR502224";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_4hr_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502225";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502226";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg30_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502227";"";"";"SRP007993";"NT2-D1 -;- malignant pluripotent embryonal carcinoma (NTera-2), \"The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.\" - ATCC. (PMID: 6694356) -;- inner cell mass";"USC_ChipSeq_NT2-D1_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502228";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502229";"";"";"SRP007993";"NT2-D1 -;- malignant pluripotent embryonal carcinoma (NTera-2), \"The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.\" - ATCC. (PMID: 6694356) -;- inner cell mass";"USC_ChipSeq_NT2-D1_SUZ12_UCDavis";"";1;"SRX150502";NA;"false";"";"";"";"";"";""
"SRR502230";"";"";"SRP007993";"NT2-D1 -;- malignant pluripotent embryonal carcinoma (NTera-2), \"The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.\" - ATCC. (PMID: 6694356) -;- inner cell mass";"USC_ChipSeq_NT2-D1_SUZ12_UCDavis";"";2;"SRX150502";NA;"false";"";"";"";"";"";""
"SRR502231";"";"";"SRP007993";"NT2-D1 -;- malignant pluripotent embryonal carcinoma (NTera-2), \"The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.\" - ATCC. (PMID: 6694356) -;- inner cell mass";"USC_ChipSeq_NT2-D1_YY1_UCDavis";"";1;"SRX150503";NA;"false";"";"";"";"";"";""
"SRR502232";"";"";"SRP007993";"NT2-D1 -;- malignant pluripotent embryonal carcinoma (NTera-2), \"The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.\" - ATCC. (PMID: 6694356) -;- inner cell mass";"USC_ChipSeq_NT2-D1_YY1_UCDavis";"";2;"SRX150503";NA;"false";"";"";"";"";"";""
"SRR502233";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_XRCC4_std";"";1;"SRX150504";NA;"false";"";"";"";"";"";""
"SRR502234";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_XRCC4_std";"";2;"SRX150504";NA;"false";"";"";"";"";"";""
"SRR502235";"";"";"SRP007993";"HCT-116 -;- colorectal carcinoma (PMID: 7214343) -;- endoderm";"USC_ChipSeq_HCT-116_Pol2_UCDavis";"";1;"SRX150505";NA;"false";"";"";"";"";"";""
"SRR502236";"";"";"SRP007993";"HCT-116 -;- colorectal carcinoma (PMID: 7214343) -;- endoderm";"USC_ChipSeq_HCT-116_Pol2_UCDavis";"";2;"SRX150505";NA;"false";"";"";"";"";"";""
"SRR502237";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg6h_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502238";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_c-Myc_std";"";1;"SRX150507";NA;"false";"";"";"";"";"";""
"SRR502239";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_c-Myc_std";"";2;"SRX150507";NA;"false";"";"";"";"";"";""
"SRR502240";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_NF-YB_std";"";1;"SRX150508";NA;"false";"";"";"";"";"";""
"SRR502241";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_NF-YB_std";"";2;"SRX150508";NA;"false";"";"";"";"";"";""
"SRR502242";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_NF-YB_std";"";3;"SRX150508";NA;"false";"";"";"";"";"";""
"SRR502243";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_BHLHE40_(NB100-1800)_IgG-mus";"";1;"SRX150509";NA;"false";"";"";"";"";"";""
"SRR502244";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_BHLHE40_(NB100-1800)_IgG-mus";"";2;"SRX150509";NA;"false";"";"";"";"";"";""
"SRR502245";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Mxi1_(AF4185)_IgG-mus";"";1;"SRX150510";NA;"false";"";"";"";"";"";""
"SRR502246";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Mxi1_(AF4185)_IgG-mus";"";2;"SRX150510";NA;"false";"";"";"";"";"";""
"SRR502247";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_CHD2_(AB68301)_IgG-rab";"";1;"SRX150511";NA;"false";"";"";"";"";"";""
"SRR502248";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_CHD2_(AB68301)_IgG-rab";"";2;"SRX150511";NA;"false";"";"";"";"";"";""
"SRR502249";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_NF-YA_std";"";1;"SRX150512";NA;"false";"";"";"";"";"";""
"SRR502250";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_NF-YA_std";"";2;"SRX150512";NA;"false";"";"";"";"";"";""
"SRR502251";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_NF-YA_std";"";3;"SRX150512";NA;"false";"";"";"";"";"";""
"SRR502252";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_JunD_IgG-rab";"";1;"SRX150513";NA;"false";"";"";"";"";"";""
"SRR502253";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_JunD_IgG-rab";"";2;"SRX150513";NA;"false";"";"";"";"";"";""
"SRR502254";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_BRF2_std";"";1;"SRX150514";NA;"false";"";"";"";"";"";""
"SRR502255";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_BRF2_std";"";2;"SRX150514";NA;"false";"";"";"";"";"";""
"SRR502256";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Znf143_(16618-1-AP)_IgG-rab";"";1;"SRX150515";NA;"false";"";"";"";"";"";""
"SRR502257";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Znf143_(16618-1-AP)_IgG-rab";"";2;"SRX150515";NA;"false";"";"";"";"";"";""
"SRR502258";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Mxi1_(AF4185)_std";"";1;"SRX150516";NA;"false";"";"";"";"";"";""
"SRR502259";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Mxi1_(AF4185)_std";"";2;"SRX150516";NA;"false";"";"";"";"";"";""
"SRR502260";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Mxi1_(AF4185)_std";"";3;"SRX150516";NA;"false";"";"";"";"";"";""
"SRR502261";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_c-Fos_Harvard_Control";"";1;"SRX150517";NA;"false";"";"";"";"";"";""
"SRR502262";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_c-Fos_Harvard_Control";"";2;"SRX150517";NA;"false";"";"";"";"";"";""
"SRR502263";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_COREST_(sc-30189)_IgG-rab";"";1;"SRX150518";NA;"false";"";"";"";"";"";""
"SRR502264";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_COREST_(sc-30189)_IgG-rab";"";2;"SRX150518";NA;"false";"";"";"";"";"";""
"SRR502265";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_BHLHE40_IgG-rab";"";1;"SRX150519";NA;"false";"";"";"";"";"";""
"SRR502266";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_BHLHE40_IgG-rab";"";2;"SRX150519";NA;"false";"";"";"";"";"";""
"SRR502267";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_c-Myc_Harvard_Control";"";1;"SRX150520";NA;"false";"";"";"";"";"";""
"SRR502268";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_c-Myc_Harvard_Control";"";2;"SRX150520";NA;"false";"";"";"";"";"";""
"SRR502269";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"USC_ChipSeq_GM12878_IKZF1_(IkN)_(UCLA)_std";"";1;"SRX150521";NA;"false";"";"";"";"";"";""
"SRR502270";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"USC_ChipSeq_GM12878_IKZF1_(IkN)_(UCLA)_std";"";2;"SRX150521";NA;"false";"";"";"";"";"";""
"SRR502271";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_insulin_Input_std";"";1;"SRX150522";NA;"false";"";"";"";"";"";""
"SRR502272";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_insulin_Input_std";"";2;"SRX150522";NA;"false";"";"";"";"";"";""
"SRR502273";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_Input_std";"";1;"SRX150523";NA;"false";"";"";"";"";"";""
"SRR502274";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_Input_std";"";2;"SRX150523";NA;"false";"";"";"";"";"";""
"SRR502275";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_GATA3_(SC-269)_UCDavis";"";1;"SRX150524";NA;"false";"";"";"";"";"";""
"SRR502276";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_GATA3_(SC-269)_UCDavis";"";2;"SRX150524";NA;"false";"";"";"";"";"";""
"SRR502277";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_GATA3_(SC-269)_UCDavis";"";3;"SRX150524";NA;"false";"";"";"";"";"";""
"SRR502278";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_TNFa_Input_IgG-rab";"";1;"SRX150525";NA;"false";"";"";"";"";"";""
"SRR502279";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_TNFa_Input_IgG-rab";"";2;"SRX150525";NA;"false";"";"";"";"";"";""
"SRR502280";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_TNFa_Input_IgG-rab";"";1;"SRX150526";NA;"false";"";"";"";"";"";""
"SRR502281";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_TNFa_Input_IgG-rab";"";2;"SRX150526";NA;"false";"";"";"";"";"";""
"SRR502282";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_TNFa_Input_IgG-rab";"";1;"SRX150527";NA;"false";"";"";"";"";"";""
"SRR502283";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_TNFa_Input_IgG-rab";"";2;"SRX150527";NA;"false";"";"";"";"";"";""
"SRR502284";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_TNFa_Input_IgG-rab";"";1;"SRX150528";NA;"false";"";"";"";"";"";""
"SRR502285";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_TNFa_Input_IgG-rab";"";2;"SRX150528";NA;"false";"";"";"";"";"";""
"SRR502286";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Input_IgG-rab";"";1;"SRX150529";NA;"false";"";"";"";"";"";""
"SRR502287";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Input_IgG-rab";"";2;"SRX150529";NA;"false";"";"";"";"";"";""
"SRR502288";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_TNFa_Input_IgG-rab";"";1;"SRX150530";NA;"false";"";"";"";"";"";""
"SRR502289";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_TNFa_Input_IgG-rab";"";2;"SRX150530";NA;"false";"";"";"";"";"";""
"SRR502290";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_TNFa_Input_IgG-rab";"";1;"SRX150531";NA;"false";"";"";"";"";"";""
"SRR502291";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_TNFa_Input_IgG-rab";"";2;"SRX150531";NA;"false";"";"";"";"";"";""
"SRR502292";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_TNFa_Input_IgG-rab";"";1;"SRX150532";NA;"false";"";"";"";"";"";""
"SRR502293";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_TNFa_Input_IgG-rab";"";2;"SRX150532";NA;"false";"";"";"";"";"";""
"SRR502294";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_TNFa_Input_IgG-rab";"";1;"SRX150533";NA;"false";"";"";"";"";"";""
"SRR502295";"";"";"SRP007993";"GM19193 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19193_TNFa_Input_IgG-rab";"";2;"SRX150533";NA;"false";"";"";"";"";"";""
"SRR502296";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_TNFa_Input_IgG-rab";"";1;"SRX150534";NA;"false";"";"";"";"";"";""
"SRR502297";"";"";"SRP007993";"GM19099 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM19099_TNFa_Input_IgG-rab";"";2;"SRX150534";NA;"false";"";"";"";"";"";""
"SRR502298";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_36hr_Pol2_std";"";1;"SRX150535";NA;"false";"";"";"";"";"";""
"SRR502299";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_36hr_Pol2_std";"";2;"SRX150535";NA;"false";"";"";"";"";"";""
"SRR502300";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_36hr_STAT3_std";"";1;"SRX150536";NA;"false";"";"";"";"";"";""
"SRR502301";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_36hr_STAT3_std";"";2;"SRX150536";NA;"false";"";"";"";"";"";""
"SRR502302";"";"";"SRP007993";"U2OS -;- osteosarcoma from the tibia of a 15 year old, J. Ponten and E. Saksela derived this line (originally 2T) in 1964 from a moderately differentiated sarcoma, viruses were not detected during co-cultivation with WI-38 cells or in CF tests against SV40, RSV or adenoviruses, mycoplasma contamination was detected and eliminated in 1972, (PMID: 6081590) -;- mesoderm";"USC_ChipSeq_U2OS_SETDB1_UCDavis";"";1;"SRX150537";NA;"false";"";"";"";"";"";""
"SRR502303";"";"";"SRP007993";"U2OS -;- osteosarcoma from the tibia of a 15 year old, J. Ponten and E. Saksela derived this line (originally 2T) in 1964 from a moderately differentiated sarcoma, viruses were not detected during co-cultivation with WI-38 cells or in CF tests against SV40, RSV or adenoviruses, mycoplasma contamination was detected and eliminated in 1972, (PMID: 6081590) -;- mesoderm";"USC_ChipSeq_U2OS_SETDB1_UCDavis";"";2;"SRX150537";NA;"false";"";"";"";"";"";""
"SRR502304";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_ZNF274_UCDavis";"";1;"SRX150538";NA;"false";"";"";"";"";"";""
"SRR502305";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_ZNF274_UCDavis";"";2;"SRX150538";NA;"false";"";"";"";"";"";""
"SRR502306";"";"";"SRP007993";"Raji -;- B lymphocyte, \"The Raji line of lymphoblast-like cells was established by R.J.V. Pulvertaft in 1963 from a Burkitt's lymphoma of the left maxilla of an 11-year-old Black male.\" - ATCC. (PMID: 14086209) -;- mesoderm";"USC_ChipSeq_Raji_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502307";"";"";"SRP007993";"Raji -;- B lymphocyte, \"The Raji line of lymphoblast-like cells was established by R.J.V. Pulvertaft in 1963 from a Burkitt's lymphoma of the left maxilla of an 11-year-old Black male.\" - ATCC. (PMID: 14086209) -;- mesoderm";"USC_ChipSeq_Raji_Pol2_UCDavis";"";1;"SRX150540";NA;"false";"";"";"";"";"";""
"SRR502308";"";"";"SRP007993";"Raji -;- B lymphocyte, \"The Raji line of lymphoblast-like cells was established by R.J.V. Pulvertaft in 1963 from a Burkitt's lymphoma of the left maxilla of an 11-year-old Black male.\" - ATCC. (PMID: 14086209) -;- mesoderm";"USC_ChipSeq_Raji_Pol2_UCDavis";"";2;"SRX150540";NA;"false";"";"";"";"";"";""
"SRR502309";"";"";"SRP007993";"PBDE -;- peripheral blood-derived erythroblasts -;- mesoderm";"USC_ChipSeq_PBDE_Pol2_UCDavis";"";1;"SRX150541";NA;"false";"";"";"";"";"";""
"SRR502310";"";"";"SRP007993";"PBDE -;- peripheral blood-derived erythroblasts -;- mesoderm";"USC_ChipSeq_PBDE_Pol2_UCDavis";"";2;"SRX150541";NA;"false";"";"";"";"";"";""
"SRR502311";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_CtBP2_UCDavis";"";1;"SRX150542";NA;"false";"";"";"";"";"";""
"SRR502312";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_CtBP2_UCDavis";"";2;"SRX150542";NA;"false";"";"";"";"";"";""
"SRR502313";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_KAP1_UCDavis";"";1;"SRX150543";NA;"false";"";"";"";"";"";""
"SRR502314";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_KAP1_UCDavis";"";2;"SRX150543";NA;"false";"";"";"";"";"";""
"SRR502315";"";"";"SRP007993";"PBDE -;- peripheral blood-derived erythroblasts -;- mesoderm";"USC_ChipSeq_PBDE_GATA-1_UCDavis";"";1;"SRX150544";NA;"false";"";"";"";"";"";""
"SRR502316";"";"";"SRP007993";"PBDE -;- peripheral blood-derived erythroblasts -;- mesoderm";"USC_ChipSeq_PBDE_GATA-1_UCDavis";"";2;"SRX150544";NA;"false";"";"";"";"";"";""
"SRR502317";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_c-Myc_std";"";1;"SRX150545";NA;"false";"";"";"";"";"";""
"SRR502318";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_c-Myc_std";"";2;"SRX150545";NA;"false";"";"";"";"";"";""
"SRR502319";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg6h_c-Jun_std";"";1;"SRX150546";NA;"false";"";"";"";"";"";""
"SRR502320";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg6h_c-Jun_std";"";2;"SRX150546";NA;"false";"";"";"";"";"";""
"SRR502321";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_c-Jun_std";"";1;"SRX150547";NA;"false";"";"";"";"";"";""
"SRR502322";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_c-Jun_std";"";2;"SRX150547";NA;"false";"";"";"";"";"";""
"SRR502323";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_STAT2_std";"";1;"SRX150548";NA;"false";"";"";"";"";"";""
"SRR502324";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_STAT2_std";"";2;"SRX150548";NA;"false";"";"";"";"";"";""
"SRR502325";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_STAT2_std";"";1;"SRX150549";NA;"false";"";"";"";"";"";""
"SRR502326";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_STAT2_std";"";2;"SRX150549";NA;"false";"";"";"";"";"";""
"SRR502327";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_STAT1_std";"";1;"SRX150550";NA;"false";"";"";"";"";"";""
"SRR502328";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_STAT1_std";"";2;"SRX150550";NA;"false";"";"";"";"";"";""
"SRR502329";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_STAT1_std";"";1;"SRX150551";NA;"false";"";"";"";"";"";""
"SRR502330";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_STAT1_std";"";2;"SRX150551";NA;"false";"";"";"";"";"";""
"SRR502331";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg6h_Pol2_std";"";1;"SRX150552";NA;"false";"";"";"";"";"";""
"SRR502332";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg6h_Pol2_std";"";2;"SRX150552";NA;"false";"";"";"";"";"";""
"SRR502333";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_Pol2_std";"";1;"SRX150553";NA;"false";"";"";"";"";"";""
"SRR502334";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa6h_Pol2_std";"";2;"SRX150553";NA;"false";"";"";"";"";"";""
"SRR502335";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_Pol2_std";"";1;"SRX150554";NA;"false";"";"";"";"";"";""
"SRR502336";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNa30_Pol2_std";"";2;"SRX150554";NA;"false";"";"";"";"";"";""
"SRR502337";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_E2F6_std";"";1;"SRX150555";NA;"false";"";"";"";"";"";""
"SRR502338";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_E2F6_std";"";2;"SRX150555";NA;"false";"";"";"";"";"";""
"SRR502339";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_HA-E2F1_UCDavis";"";1;"SRX150556";NA;"false";"";"";"";"";"";""
"SRR502340";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_HA-E2F1_UCDavis";"";2;"SRX150556";NA;"false";"";"";"";"";"";""
"SRR502341";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TNFa_NFKB_IgG-rab";"";1;"SRX150557";NA;"false";"";"";"";"";"";""
"SRR502342";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TNFa_NFKB_IgG-rab";"";2;"SRX150557";NA;"false";"";"";"";"";"";""
"SRR502343";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TNFa_NFKB_IgG-rab";"";3;"SRX150557";NA;"false";"";"";"";"";"";""
"SRR502344";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TNFa_NFKB_IgG-rab";"";4;"SRX150557";NA;"false";"";"";"";"";"";""
"SRR502345";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_ZNF274_UCDavis";"";1;"SRX150558";NA;"false";"";"";"";"";"";""
"SRR502346";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_ZNF274_UCDavis";"";2;"SRX150558";NA;"false";"";"";"";"";"";""
"SRR502347";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"USC_ChipSeq_GM12878_TR4_std";"";1;"SRX150559";NA;"false";"";"";"";"";"";""
"SRR502348";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"USC_ChipSeq_GM12878_TR4_std";"";2;"SRX150559";NA;"false";"";"";"";"";"";""
"SRR502349";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Pol3_std";"";1;"SRX150560";NA;"false";"";"";"";"";"";""
"SRR502350";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Pol3_std";"";2;"SRX150560";NA;"false";"";"";"";"";"";""
"SRR502351";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"USC_ChipSeq_GM12878_YY1_std";"";1;"SRX150561";NA;"false";"";"";"";"";"";""
"SRR502352";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"USC_ChipSeq_GM12878_YY1_std";"";2;"SRX150561";NA;"false";"";"";"";"";"";""
"SRR502353";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_ZZZ3_std";"";1;"SRX150562";NA;"false";"";"";"";"";"";""
"SRR502354";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_ZZZ3_std";"";2;"SRX150562";NA;"false";"";"";"";"";"";""
"SRR502355";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_E2F1_std";"";1;"SRX150563";NA;"false";"";"";"";"";"";""
"SRR502356";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_E2F1_std";"";2;"SRX150563";NA;"false";"";"";"";"";"";""
"SRR502357";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_Input_UCDavis";"";1;"SRX150564";NA;"false";"";"";"";"";"";""
"SRR502358";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_Input_UCDavis";"";2;"SRX150564";NA;"false";"";"";"";"";"";""
"SRR502359";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_BDP1_std";"";1;"SRX150565";NA;"false";"";"";"";"";"";""
"SRR502360";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_BDP1_std";"";2;"SRX150565";NA;"false";"";"";"";"";"";""
"SRR502361";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg30_STAT1_std";"";1;"SRX150566";NA;"false";"";"";"";"";"";""
"SRR502362";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg30_STAT1_std";"";2;"SRX150566";NA;"false";"";"";"";"";"";""
"SRR502363";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg6h_STAT1_std";"";1;"SRX150567";NA;"false";"";"";"";"";"";""
"SRR502364";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg6h_STAT1_std";"";2;"SRX150567";NA;"false";"";"";"";"";"";""
"SRR502365";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_RPC155_std";"";1;"SRX150568";NA;"false";"";"";"";"";"";""
"SRR502366";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_RPC155_std";"";2;"SRX150568";NA;"false";"";"";"";"";"";""
"SRR502367";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BRF2_std";"";1;"SRX150569";NA;"false";"";"";"";"";"";""
"SRR502368";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BRF2_std";"";2;"SRX150569";NA;"false";"";"";"";"";"";""
"SRR502369";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BRF2_std";"";3;"SRX150569";NA;"false";"";"";"";"";"";""
"SRR502370";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_4hr_c-Myc_Harvard_Control";"";1;"SRX150570";NA;"false";"";"";"";"";"";""
"SRR502371";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_4OHTAM_1uM_4hr_c-Myc_Harvard_Control";"";2;"SRX150570";NA;"false";"";"";"";"";"";""
"SRR502372";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_WHIP_IgG-mus";"";1;"SRX150571";NA;"false";"";"";"";"";"";""
"SRR502373";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_WHIP_IgG-mus";"";2;"SRX150571";NA;"false";"";"";"";"";"";""
"SRR502374";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_CEBPB_IgG-rab";"";1;"SRX150572";NA;"false";"";"";"";"";"";""
"SRR502375";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_CEBPB_IgG-rab";"";2;"SRX150572";NA;"false";"";"";"";"";"";""
"SRR502376";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_p300_(SC-48343)_IgG-rab";"";1;"SRX150573";NA;"false";"";"";"";"";"";""
"SRR502377";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_p300_(SC-48343)_IgG-rab";"";2;"SRX150573";NA;"false";"";"";"";"";"";""
"SRR502378";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_TBP_IgG-mus";"";1;"SRX150574";NA;"false";"";"";"";"";"";""
"SRR502379";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_TBP_IgG-mus";"";2;"SRX150574";NA;"false";"";"";"";"";"";""
"SRR502380";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_TAL1_(SC-12984)_IgG-mus";"";1;"SRX150575";NA;"false";"";"";"";"";"";""
"SRR502381";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_TAL1_(SC-12984)_IgG-mus";"";2;"SRX150575";NA;"false";"";"";"";"";"";""
"SRR502382";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Mxi1_(AF4185)_IgG-rab";"";1;"SRX150576";NA;"false";"";"";"";"";"";""
"SRR502383";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Mxi1_(AF4185)_IgG-rab";"";2;"SRX150576";NA;"false";"";"";"";"";"";""
"SRR502384";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Mxi1_(AF4185)_IgG-rab";"";1;"SRX150577";NA;"false";"";"";"";"";"";""
"SRR502385";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Mxi1_(AF4185)_IgG-rab";"";2;"SRX150577";NA;"false";"";"";"";"";"";""
"SRR502386";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_CEBPB_IgG-rab";"";1;"SRX150578";NA;"false";"";"";"";"";"";""
"SRR502387";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_CEBPB_IgG-rab";"";2;"SRX150578";NA;"false";"";"";"";"";"";""
"SRR502388";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_p300_(SC-584)_IgG-rab";"";1;"SRX150579";NA;"false";"";"";"";"";"";""
"SRR502389";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_p300_(SC-584)_IgG-rab";"";2;"SRX150579";NA;"false";"";"";"";"";"";""
"SRR502390";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_GTF2F1_(AB28179)_IgG-rab";"";1;"SRX150580";NA;"false";"";"";"";"";"";""
"SRR502391";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_GTF2F1_(AB28179)_IgG-rab";"";2;"SRX150580";NA;"false";"";"";"";"";"";""
"SRR502392";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_CHD2_(AB68301)_IgG-rab";"";1;"SRX150581";NA;"false";"";"";"";"";"";""
"SRR502393";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_CHD2_(AB68301)_IgG-rab";"";2;"SRX150581";NA;"false";"";"";"";"";"";""
"SRR502394";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_ZNF274_(M01)_UCDavis";"";1;"SRX150582";NA;"false";"";"";"";"";"";""
"SRR502395";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_ZNF274_(M01)_UCDavis";"";2;"SRX150582";NA;"false";"";"";"";"";"";""
"SRR502396";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNa6h_IRF1_std";"";1;"SRX150583";NA;"false";"";"";"";"";"";""
"SRR502397";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNa6h_IRF1_std";"";2;"SRX150583";NA;"false";"";"";"";"";"";""
"SRR502398";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg30_IRF1_std";"";1;"SRX150584";NA;"false";"";"";"";"";"";""
"SRR502399";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg30_IRF1_std";"";2;"SRX150584";NA;"false";"";"";"";"";"";""
"SRR502400";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_NF-YA_IgG-mus";"";1;"SRX150585";NA;"false";"";"";"";"";"";""
"SRR502401";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_NF-YA_IgG-mus";"";2;"SRX150585";NA;"false";"";"";"";"";"";""
"SRR502402";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_NF-YB_IgG-mus";"";1;"SRX150586";NA;"false";"";"";"";"";"";""
"SRR502403";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Harvard_ChipSeq_GM12878_NF-YB_IgG-mus";"";2;"SRX150586";NA;"false";"";"";"";"";"";""
"SRR502404";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_NF-YA_IgG-rab";"";1;"SRX150587";NA;"false";"";"";"";"";"";""
"SRR502405";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_NF-YA_IgG-rab";"";2;"SRX150587";NA;"false";"";"";"";"";"";""
"SRR502406";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_c-Myc_IgG-rab";"";1;"SRX150588";NA;"false";"";"";"";"";"";""
"SRR502407";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_c-Myc_IgG-rab";"";2;"SRX150588";NA;"false";"";"";"";"";"";""
"SRR502408";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Yale_ChipSeq_HUVEC_Input_std";"";1;"SRX150589";NA;"false";"";"";"";"";"";""
"SRR502409";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Yale_ChipSeq_HUVEC_Input_std";"";2;"SRX150589";NA;"false";"";"";"";"";"";""
"SRR502410";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Brg1_IgG-mus";"";1;"SRX150590";NA;"false";"";"";"";"";"";""
"SRR502411";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Brg1_IgG-mus";"";2;"SRX150590";NA;"false";"";"";"";"";"";""
"SRR502412";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Brg1_IgG-mus";"";3;"SRX150590";NA;"false";"";"";"";"";"";""
"SRR502413";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_Input_IgG-rab";"";1;"SRX150591";NA;"false";"";"";"";"";"";""
"SRR502414";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_Input_IgG-rab";"";2;"SRX150591";NA;"false";"";"";"";"";"";""
"SRR502415";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_Pol2_IgG-rab";"";1;"SRX150592";NA;"false";"";"";"";"";"";""
"SRR502416";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_Pol2_IgG-rab";"";2;"SRX150592";NA;"false";"";"";"";"";"";""
"SRR502417";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Znf143_(16618-1-AP)_IgG-rab";"";1;"SRX150593";NA;"false";"";"";"";"";"";""
"SRR502418";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Znf143_(16618-1-AP)_IgG-rab";"";2;"SRX150593";NA;"false";"";"";"";"";"";""
"SRR502419";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Input_IgG-goat";"";1;"SRX150594";NA;"false";"";"";"";"";"";""
"SRR502420";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Input_IgG-goat";"";2;"SRX150594";NA;"false";"";"";"";"";"";""
"SRR502421";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_c-Myc_IgG-rab";"";1;"SRX150595";NA;"false";"";"";"";"";"";""
"SRR502422";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_c-Myc_IgG-rab";"";2;"SRX150595";NA;"false";"";"";"";"";"";""
"SRR502423";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_BRCA1_(A300-000A)_IgG-rab";"";1;"SRX150596";NA;"false";"";"";"";"";"";""
"SRR502424";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_BRCA1_(A300-000A)_IgG-rab";"";2;"SRX150596";NA;"false";"";"";"";"";"";""
"SRR502425";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Max_IgG-mus";"";1;"SRX150597";NA;"false";"";"";"";"";"";""
"SRR502426";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Max_IgG-mus";"";2;"SRX150597";NA;"false";"";"";"";"";"";""
"SRR502427";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_CEBPB_IgG-rab";"";1;"SRX150598";NA;"false";"";"";"";"";"";""
"SRR502428";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_CEBPB_IgG-rab";"";2;"SRX150598";NA;"false";"";"";"";"";"";""
"SRR502429";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_MafF_(M8194)_IgG-rab";"";1;"SRX150599";NA;"false";"";"";"";"";"";""
"SRR502430";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_MafF_(M8194)_IgG-rab";"";2;"SRX150599";NA;"false";"";"";"";"";"";""
"SRR502431";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNa30_c-Jun_std";"";1;"SRX150600";NA;"false";"";"";"";"";"";""
"SRR502432";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNa30_c-Jun_std";"";2;"SRX150600";NA;"false";"";"";"";"";"";""
"SRR502433";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_Pol2_IgG-mus";"";1;"SRX150601";NA;"false";"";"";"";"";"";""
"SRR502434";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_Pol2_IgG-mus";"";2;"SRX150601";NA;"false";"";"";"";"";"";""
"SRR502435";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_Pol2_IgG-mus";"";3;"SRX150601";NA;"false";"";"";"";"";"";""
"SRR502436";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_Pol2_IgG-mus";"";4;"SRX150601";NA;"false";"";"";"";"";"";""
"SRR502437";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_Input_IgG-mus";"";1;"SRX150602";NA;"false";"";"";"";"";"";""
"SRR502438";"";"";"SRP007993";"GM18505 -;- lymphoblastoid, International HapMap Project, Yoruba in Ibadan, Nigera, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18505_Input_IgG-mus";"";2;"SRX150602";NA;"false";"";"";"";"";"";""
"SRR502439";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_Pol2_IgG-mus";"";1;"SRX150603";NA;"false";"";"";"";"";"";""
"SRR502440";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_Pol2_IgG-mus";"";2;"SRX150603";NA;"false";"";"";"";"";"";""
"SRR502441";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_Pol2_IgG-mus";"";3;"SRX150603";NA;"false";"";"";"";"";"";""
"SRR502442";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_Input_IgG-mus";"";1;"SRX150604";NA;"false";"";"";"";"";"";""
"SRR502443";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_Input_IgG-mus";"";2;"SRX150604";NA;"false";"";"";"";"";"";""
"SRR502444";"";"";"SRP007993";"GM18526 -;- lymphoblastoid, International HapMap Project, Han Chinese in Beijing, China, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18526_Input_IgG-mus";"";3;"SRX150604";NA;"false";"";"";"";"";"";""
"SRR502445";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_TNFa_NFKB_IgG-rab";"";1;"SRX150605";NA;"false";"";"";"";"";"";""
"SRR502446";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_TNFa_NFKB_IgG-rab";"";2;"SRX150605";NA;"false";"";"";"";"";"";""
"SRR502447";"";"";"SRP007993";"GM12891 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12891_TNFa_NFKB_IgG-rab";"";3;"SRX150605";NA;"false";"";"";"";"";"";""
"SRR502448";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_TNFa_NFKB_IgG-rab";"";1;"SRX150606";NA;"false";"";"";"";"";"";""
"SRR502449";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_TNFa_NFKB_IgG-rab";"";2;"SRX150606";NA;"false";"";"";"";"";"";""
"SRR502450";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_TNFa_NFKB_IgG-rab";"";3;"SRX150606";NA;"false";"";"";"";"";"";""
"SRR502451";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_TNFa_NFKB_IgG-rab";"";4;"SRX150606";NA;"false";"";"";"";"";"";""
"SRR502452";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_TNFa_NFKB_IgG-rab";"";5;"SRX150606";NA;"false";"";"";"";"";"";""
"SRR502453";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_Input_IgG-mus";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502454";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_TNFa_NFKB_IgG-rab";"";1;"SRX150608";NA;"false";"";"";"";"";"";""
"SRR502455";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_TNFa_NFKB_IgG-rab";"";2;"SRX150608";NA;"false";"";"";"";"";"";""
"SRR502456";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_TNFa_NFKB_IgG-rab";"";3;"SRX150608";NA;"false";"";"";"";"";"";""
"SRR502457";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_TNFa_NFKB_IgG-rab";"";4;"SRX150608";NA;"false";"";"";"";"";"";""
"SRR502458";"";"";"SRP007993";"GM15510 -;- lymphoblastoid NIGMS Human Genetic Cell Repository, DNA Polymorphism Discovery Resource Collection, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM15510_TNFa_NFKB_IgG-rab";"";5;"SRX150608";NA;"false";"";"";"";"";"";""
"SRR502459";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_Pol2_IgG-mus";"";1;"SRX150609";NA;"false";"";"";"";"";"";""
"SRR502460";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_Pol2_IgG-mus";"";2;"SRX150609";NA;"false";"";"";"";"";"";""
"SRR502461";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_Pol2_IgG-mus";"";3;"SRX150609";NA;"false";"";"";"";"";"";""
"SRR502462";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_Pol2_IgG-mus";"";4;"SRX150609";NA;"false";"";"";"";"";"";""
"SRR502463";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_TNFa_NFKB_IgG-rab";"";1;"SRX150610";NA;"false";"";"";"";"";"";""
"SRR502464";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_TNFa_NFKB_IgG-rab";"";2;"SRX150610";NA;"false";"";"";"";"";"";""
"SRR502465";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_TNFa_NFKB_IgG-rab";"";3;"SRX150610";NA;"false";"";"";"";"";"";""
"SRR502466";"";"";"SRP007993";"GM18951 -;- lymphoblastoid, International HapMap Project, Japanese in Tokyo, Japan, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM18951_TNFa_NFKB_IgG-rab";"";4;"SRX150610";NA;"false";"";"";"";"";"";""
"SRR502467";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_ZNF263_UCDavis";"";1;"SRX150611";NA;"false";"";"";"";"";"";""
"SRR502468";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_ZNF263_UCDavis";"";2;"SRX150611";NA;"false";"";"";"";"";"";""
"SRR502469";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"Yale_ChipSeq_HEK293_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502470";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"Yale_ChipSeq_HEK293_Pol2_std";"";1;"SRX150613";NA;"false";"";"";"";"";"";""
"SRR502471";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"Yale_ChipSeq_HEK293_Pol2_std";"";2;"SRX150613";NA;"false";"";"";"";"";"";""
"SRR502472";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"Yale_ChipSeq_HEK293_Pol2_std";"";3;"SRX150613";NA;"false";"";"";"";"";"";""
"SRR502473";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_IgG-mus";"";1;"SRX150614";NA;"false";"";"";"";"";"";""
"SRR502474";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_IgG-mus";"";2;"SRX150614";NA;"false";"";"";"";"";"";""
"SRR502475";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_Large_Fragment";"";1;"SRX150615";NA;"false";"";"";"";"";"";""
"SRR502476";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_Large_Fragment";"";2;"SRX150615";NA;"false";"";"";"";"";"";""
"SRR502477";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_MNase";"";1;"SRX150616";NA;"false";"";"";"";"";"";""
"SRR502478";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_MNase";"";2;"SRX150616";NA;"false";"";"";"";"";"";""
"SRR502479";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_Naked_DNA";"";1;"SRX150617";NA;"false";"";"";"";"";"";""
"SRR502480";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_Naked_DNA";"";2;"SRX150617";NA;"false";"";"";"";"";"";""
"SRR502481";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Yale_ChipSeq_HeLa-S3_Input_Naked_DNA";"";3;"SRX150617";NA;"false";"";"";"";"";"";""
"SRR502482";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_Max_std";"";1;"SRX150618";NA;"false";"";"";"";"";"";""
"SRR502483";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_Max_std";"";2;"SRX150618";NA;"false";"";"";"";"";"";""
"SRR502484";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_GATA-1_UCDavis";"";1;"SRX150619";NA;"false";"";"";"";"";"";""
"SRR502485";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_GATA-1_UCDavis";"";2;"SRX150619";NA;"false";"";"";"";"";"";""
"SRR502486";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Yale_ChipSeq_GM12878_JunD_std";"";1;"SRX150620";NA;"false";"";"";"";"";"";""
"SRR502487";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Yale_ChipSeq_GM12878_JunD_std";"";2;"SRX150620";NA;"false";"";"";"";"";"";""
"SRR502488";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_SMC3_(ab9263)_IgG-rab";"";1;"SRX150621";NA;"false";"";"";"";"";"";""
"SRR502489";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_SMC3_(ab9263)_IgG-rab";"";2;"SRX150621";NA;"false";"";"";"";"";"";""
"SRR502490";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Pol2(phosphoS2)_IgG-rab";"";1;"SRX150622";NA;"false";"";"";"";"";"";""
"SRR502491";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Pol2(phosphoS2)_IgG-rab";"";2;"SRX150622";NA;"false";"";"";"";"";"";""
"SRR502492";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_HMGN3_std";"";1;"SRX150623";NA;"false";"";"";"";"";"";""
"SRR502493";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_HMGN3_std";"";2;"SRX150623";NA;"false";"";"";"";"";"";""
"SRR502494";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_p300_(SC-584)_IgG-rab";"";1;"SRX150624";NA;"false";"";"";"";"";"";""
"SRR502495";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_p300_(SC-584)_IgG-rab";"";2;"SRX150624";NA;"false";"";"";"";"";"";""
"SRR502496";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNa30_IRF1_std";"";1;"SRX150625";NA;"false";"";"";"";"";"";""
"SRR502497";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNa30_IRF1_std";"";2;"SRX150625";NA;"false";"";"";"";"";"";""
"SRR502498";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_CCNT2_std";"";1;"SRX150626";NA;"false";"";"";"";"";"";""
"SRR502499";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_CCNT2_std";"";2;"SRX150626";NA;"false";"";"";"";"";"";""
"SRR502500";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg30_c-Myc_std";"";1;"SRX150627";NA;"false";"";"";"";"";"";""
"SRR502501";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg30_c-Myc_std";"";2;"SRX150627";NA;"false";"";"";"";"";"";""
"SRR502502";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg6h_IRF1_std";"";1;"SRX150628";NA;"false";"";"";"";"";"";""
"SRR502503";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_IFNg6h_IRF1_std";"";2;"SRX150628";NA;"false";"";"";"";"";"";""
"SRR502504";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_12hr_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502505";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_12hr_STAT3_std";"";1;"SRX150630";NA;"false";"";"";"";"";"";""
"SRR502506";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_12hr_STAT3_std";"";2;"SRX150630";NA;"false";"";"";"";"";"";""
"SRR502507";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_BRCA1_(A300-000A)_IgG-rab";"";1;"SRX150631";NA;"false";"";"";"";"";"";""
"SRR502508";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_BRCA1_(A300-000A)_IgG-rab";"";2;"SRX150631";NA;"false";"";"";"";"";"";""
"SRR502509";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_CEBPB_IgG-rab";"";1;"SRX150632";NA;"false";"";"";"";"";"";""
"SRR502510";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_CEBPB_IgG-rab";"";2;"SRX150632";NA;"false";"";"";"";"";"";""
"SRR502511";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_GTF2F1_(AB28179)_IgG-rab";"";1;"SRX150633";NA;"false";"";"";"";"";"";""
"SRR502512";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_GTF2F1_(AB28179)_IgG-rab";"";2;"SRX150633";NA;"false";"";"";"";"";"";""
"SRR502513";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_PRDM1_(9115)_IgG-rab";"";1;"SRX150634";NA;"false";"";"";"";"";"";""
"SRR502514";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_PRDM1_(9115)_IgG-rab";"";2;"SRX150634";NA;"false";"";"";"";"";"";""
"SRR502515";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_RFX5_(200-401-194)_IgG-mus";"";1;"SRX150635";NA;"false";"";"";"";"";"";""
"SRR502516";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_RFX5_(200-401-194)_IgG-mus";"";2;"SRX150635";NA;"false";"";"";"";"";"";""
"SRR502517";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_STAT3_IgG-mus";"";1;"SRX150636";NA;"false";"";"";"";"";"";""
"SRR502518";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_STAT3_IgG-mus";"";2;"SRX150636";NA;"false";"";"";"";"";"";""
"SRR502519";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_USF2_IgG-mus";"";1;"SRX150637";NA;"false";"";"";"";"";"";""
"SRR502520";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_USF2_IgG-mus";"";2;"SRX150637";NA;"false";"";"";"";"";"";""
"SRR502521";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_p300_(SC-584)_IgG-mus";"";1;"SRX150638";NA;"false";"";"";"";"";"";""
"SRR502522";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_p300_(SC-584)_IgG-mus";"";2;"SRX150638";NA;"false";"";"";"";"";"";""
"SRR502523";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_RFX5_(200-401-194)_IgG-rab";"";1;"SRX150639";NA;"false";"";"";"";"";"";""
"SRR502524";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_RFX5_(200-401-194)_IgG-rab";"";2;"SRX150639";NA;"false";"";"";"";"";"";""
"SRR502525";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_USF2_IgG-mus";"";1;"SRX150640";NA;"false";"";"";"";"";"";""
"SRR502526";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_USF2_IgG-mus";"";2;"SRX150640";NA;"false";"";"";"";"";"";""
"SRR502527";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_p300_(SC-584)_std";"";1;"SRX150641";NA;"false";"";"";"";"";"";""
"SRR502528";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_p300_(SC-584)_std";"";2;"SRX150641";NA;"false";"";"";"";"";"";""
"SRR502529";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_ZNF217_UCDavis";"";1;"SRX150642";NA;"false";"";"";"";"";"";""
"SRR502530";"";"";"SRP007993";"MCF-7 -;- mammary gland, adenocarcinoma. (PMID: 4357757), newly promoted to tier 2: not in 2011 analysis -;- ectoderm";"USC_ChipSeq_MCF-7_ZNF217_UCDavis";"";2;"SRX150642";NA;"false";"";"";"";"";"";""
"SRR502531";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TNFa_Input_IgG-rab";"";1;"SRX150643";NA;"false";"";"";"";"";"";""
"SRR502532";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TNFa_Input_IgG-rab";"";2;"SRX150643";NA;"false";"";"";"";"";"";""
"SRR502533";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_RFX5_(200-401-194)_IgG-rab";"";1;"SRX150644";NA;"false";"";"";"";"";"";""
"SRR502534";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_RFX5_(200-401-194)_IgG-rab";"";2;"SRX150644";NA;"false";"";"";"";"";"";""
"SRR502535";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_RFX5_(200-401-194)_IgG-rab";"";3;"SRX150644";NA;"false";"";"";"";"";"";""
"SRR502536";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_BHLHE40_(NB100-1800)_IgG-rab";"";1;"SRX150645";NA;"false";"";"";"";"";"";""
"SRR502537";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_BHLHE40_(NB100-1800)_IgG-rab";"";2;"SRX150645";NA;"false";"";"";"";"";"";""
"SRR502538";"";"";"SRP007993";"SH-SY5Y -;- neuroblastoma clonal subline of the neuroepithelioma cell line SK-N-SH from the 1970 bone marrow biopsy of a 4-year-old girl with metastatic neuroblastoma, trisomy of 1q -;- ectoderm";"USC_ChipSeq_SH-SY5Y_GATA3_(SC-269)_UCDavis";"";1;"SRX150646";NA;"false";"";"";"";"";"";""
"SRR502539";"";"";"SRP007993";"SH-SY5Y -;- neuroblastoma clonal subline of the neuroepithelioma cell line SK-N-SH from the 1970 bone marrow biopsy of a 4-year-old girl with metastatic neuroblastoma, trisomy of 1q -;- ectoderm";"USC_ChipSeq_SH-SY5Y_GATA3_(SC-269)_UCDavis";"";2;"SRX150646";NA;"false";"";"";"";"";"";""
"SRR502540";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Znf143_(16618-1-AP)_IgG-rab";"";1;"SRX150647";NA;"false";"";"";"";"";"";""
"SRR502541";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Znf143_(16618-1-AP)_IgG-rab";"";2;"SRX150647";NA;"false";"";"";"";"";"";""
"SRR502542";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_JunD_IgG-rab";"";1;"SRX150648";NA;"false";"";"";"";"";"";""
"SRR502543";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_JunD_IgG-rab";"";2;"SRX150648";NA;"false";"";"";"";"";"";""
"SRR502544";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_IRF3_IgG-rab";"";1;"SRX150649";NA;"false";"";"";"";"";"";""
"SRR502545";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_IRF3_IgG-rab";"";2;"SRX150649";NA;"false";"";"";"";"";"";""
"SRR502546";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Rad21_IgG-rab";"";1;"SRX150650";NA;"false";"";"";"";"";"";""
"SRR502547";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Rad21_IgG-rab";"";2;"SRX150650";NA;"false";"";"";"";"";"";""
"SRR502548";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Stanford_ChipSeq_HUVEC_Max_std";"";1;"SRX150651";NA;"false";"";"";"";"";"";""
"SRR502549";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"Stanford_ChipSeq_HUVEC_Max_std";"";2;"SRX150651";NA;"false";"";"";"";"";"";""
"SRR502550";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_MNaseD_SETDB1_UCDavis";"";1;"SRX150652";NA;"false";"";"";"";"";"";""
"SRR502551";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_MNaseD_SETDB1_UCDavis";"";2;"SRX150652";NA;"false";"";"";"";"";"";""
"SRR502552";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_TBLR1_(NB600-270)_IgG-rab";"";1;"SRX150653";NA;"false";"";"";"";"";"";""
"SRR502553";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_TBLR1_(NB600-270)_IgG-rab";"";2;"SRX150653";NA;"false";"";"";"";"";"";""
"SRR502554";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_TBLR1_(ab24550)_IgG-rab";"";1;"SRX150654";NA;"false";"";"";"";"";"";""
"SRR502555";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_TBLR1_(ab24550)_IgG-rab";"";2;"SRX150654";NA;"false";"";"";"";"";"";""
"SRR502556";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Bach1_(sc-14700)_IgG-rab";"";1;"SRX150655";NA;"false";"";"";"";"";"";""
"SRR502557";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Bach1_(sc-14700)_IgG-rab";"";2;"SRX150655";NA;"false";"";"";"";"";"";""
"SRR502558";"";"";"SRP007993";"HEK293-T-REx -;- embryonic kidney cells transformed with Adenovirus 5 DNA stably expressing tetracycline repressor, HEK293 (ATCC number CRL-1573) is the parental cell line, hypotriploid, XXX -;- mesoderm";"USC_ChipSeq_HEK293-T-REx_ZNF263_UCDavis";"";1;"SRX150656";NA;"false";"";"";"";"";"";""
"SRR502559";"";"";"SRP007993";"HEK293-T-REx -;- embryonic kidney cells transformed with Adenovirus 5 DNA stably expressing tetracycline repressor, HEK293 (ATCC number CRL-1573) is the parental cell line, hypotriploid, XXX -;- mesoderm";"USC_ChipSeq_HEK293-T-REx_ZNF263_UCDavis";"";2;"SRX150656";NA;"false";"";"";"";"";"";""
"SRR502560";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_COREST_(sc-30189)_IgG-rab";"";1;"SRX150657";NA;"false";"";"";"";"";"";""
"SRR502561";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_COREST_(sc-30189)_IgG-rab";"";2;"SRX150657";NA;"false";"";"";"";"";"";""
"SRR502562";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_COREST_(sc-30189)_IgG-rab";"";1;"SRX150658";NA;"false";"";"";"";"";"";""
"SRR502563";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_COREST_(sc-30189)_IgG-rab";"";2;"SRX150658";NA;"false";"";"";"";"";"";""
"SRR502564";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Bach1_(sc-14700)_IgG-rab";"";1;"SRX150659";NA;"false";"";"";"";"";"";""
"SRR502565";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_Bach1_(sc-14700)_IgG-rab";"";2;"SRX150659";NA;"false";"";"";"";"";"";""
"SRR502566";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_GTF2F1_(AB28179)_IgG-rab";"";1;"SRX150660";NA;"false";"";"";"";"";"";""
"SRR502567";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_GTF2F1_(AB28179)_IgG-rab";"";2;"SRX150660";NA;"false";"";"";"";"";"";""
"SRR502568";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_BRF1_std";"";1;"SRX150661";NA;"false";"";"";"";"";"";""
"SRR502569";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Harvard_ChipSeq_HeLa-S3_BRF1_std";"";2;"SRX150661";NA;"false";"";"";"";"";"";""
"SRR502570";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_COREST_(sc-30189)_IgG-mus";"";1;"SRX150662";NA;"false";"";"";"";"";"";""
"SRR502571";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_COREST_(sc-30189)_IgG-mus";"";2;"SRX150662";NA;"false";"";"";"";"";"";""
"SRR502572";"";"";"SRP007993";"NT2-D1 -;- malignant pluripotent embryonal carcinoma (NTera-2), \"The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.\" - ATCC. (PMID: 6694356) -;- inner cell mass";"USC_ChipSeq_NT2-D1_ZNF274_UCDavis";"";1;"SRX150663";NA;"false";"";"";"";"";"";""
"SRR502573";"";"";"SRP007993";"NT2-D1 -;- malignant pluripotent embryonal carcinoma (NTera-2), \"The NTERA-2 cl.D1 cell line is a pluripotent human testicular embryonal carcinoma cell line derived by cloning the NTERA-2 cell line.\" - ATCC. (PMID: 6694356) -;- inner cell mass";"USC_ChipSeq_NT2-D1_ZNF274_UCDavis";"";2;"SRX150663";NA;"false";"";"";"";"";"";""
"SRR502574";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"USC_ChipSeq_HUVEC_c-Fos_UCDavis";"";1;"SRX150664";NA;"false";"";"";"";"";"";""
"SRR502575";"";"";"SRP007993";"HUVEC -;- umbilical vein endothelial cells -;- mesoderm";"USC_ChipSeq_HUVEC_c-Fos_UCDavis";"";2;"SRX150664";NA;"false";"";"";"";"";"";""
"SRR502576";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"USC_ChipSeq_HEK293_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502577";"";"";"SRP007993";"U2OS -;- osteosarcoma from the tibia of a 15 year old, J. Ponten and E. Saksela derived this line (originally 2T) in 1964 from a moderately differentiated sarcoma, viruses were not detected during co-cultivation with WI-38 cells or in CF tests against SV40, RSV or adenoviruses, mycoplasma contamination was detected and eliminated in 1972, (PMID: 6081590) -;- mesoderm";"USC_ChipSeq_U2OS_KAP1_UCDavis";"";1;"SRX150666";NA;"false";"";"";"";"";"";""
"SRR502578";"";"";"SRP007993";"U2OS -;- osteosarcoma from the tibia of a 15 year old, J. Ponten and E. Saksela derived this line (originally 2T) in 1964 from a moderately differentiated sarcoma, viruses were not detected during co-cultivation with WI-38 cells or in CF tests against SV40, RSV or adenoviruses, mycoplasma contamination was detected and eliminated in 1972, (PMID: 6081590) -;- mesoderm";"USC_ChipSeq_U2OS_KAP1_UCDavis";"";2;"SRX150666";NA;"false";"";"";"";"";"";""
"SRR502579";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_Pol2_std";"";1;"SRX150667";NA;"false";"";"";"";"";"";""
"SRR502580";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_Pol2_std";"";2;"SRX150667";NA;"false";"";"";"";"";"";""
"SRR502581";"";"";"SRP007993";"SH-SY5Y -;- neuroblastoma clonal subline of the neuroepithelioma cell line SK-N-SH from the 1970 bone marrow biopsy of a 4-year-old girl with metastatic neuroblastoma, trisomy of 1q -;- ectoderm";"USC_ChipSeq_SH-SY5Y_GATA-2_UCDavis";"";1;"SRX150668";NA;"false";"";"";"";"";"";""
"SRR502582";"";"";"SRP007993";"SH-SY5Y -;- neuroblastoma clonal subline of the neuroepithelioma cell line SK-N-SH from the 1970 bone marrow biopsy of a 4-year-old girl with metastatic neuroblastoma, trisomy of 1q -;- ectoderm";"USC_ChipSeq_SH-SY5Y_GATA-2_UCDavis";"";2;"SRX150668";NA;"false";"";"";"";"";"";""
"SRR502583";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"USC_ChipSeq_HEK293_ELK4_UCDavis";"";1;"SRX150669";NA;"false";"";"";"";"";"";""
"SRR502584";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"USC_ChipSeq_HEK293_ELK4_UCDavis";"";2;"SRX150669";NA;"false";"";"";"";"";"";""
"SRR502585";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_STAT3_std";"";1;"SRX150670";NA;"false";"";"";"";"";"";""
"SRR502586";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_EtOH_0.01pct_STAT3_std";"";2;"SRX150670";NA;"false";"";"";"";"";"";""
"SRR502587";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"USC_ChipSeq_HEK293_KAP1_UCDavis";"";1;"SRX150671";NA;"false";"";"";"";"";"";""
"SRR502588";"";"";"SRP007993";"HEK293 -;- embryonic kidney, cells contain Adenovirus 5 DNA (PMID: 11967234) -;- mesoderm";"USC_ChipSeq_HEK293_KAP1_UCDavis";"";2;"SRX150671";NA;"false";"";"";"";"";"";""
"SRR502589";"";"";"SRP007993";"PBDE -;- peripheral blood-derived erythroblasts -;- mesoderm";"USC_ChipSeq_PBDE_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502590";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BDP1_std";"";1;"SRX150673";NA;"false";"";"";"";"";"";""
"SRR502591";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BDP1_std";"";2;"SRX150673";NA;"false";"";"";"";"";"";""
"SRR502592";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BDP1_std";"";3;"SRX150673";NA;"false";"";"";"";"";"";""
"SRR502593";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BRF1_std";"";1;"SRX150674";NA;"false";"";"";"";"";"";""
"SRR502594";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BRF1_std";"";2;"SRX150674";NA;"false";"";"";"";"";"";""
"SRR502595";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Harvard_ChipSeq_K562_BRF1_std";"";3;"SRX150674";NA;"false";"";"";"";"";"";""
"SRR502596";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"USC_ChipSeq_HepG2_TR4_UCDavis";"";1;"SRX150675";NA;"false";"";"";"";"";"";""
"SRR502597";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"USC_ChipSeq_HepG2_TR4_UCDavis";"";2;"SRX150675";NA;"false";"";"";"";"";"";""
"SRR502598";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_E2F6_UCDavis";"";1;"SRX150676";NA;"false";"";"";"";"";"";""
"SRR502599";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_E2F6_UCDavis";"";2;"SRX150676";NA;"false";"";"";"";"";"";""
"SRR502600";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_SETDB1_UCDavis";"";1;"SRX150677";NA;"false";"";"";"";"";"";""
"SRR502601";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_SETDB1_UCDavis";"";2;"SRX150677";NA;"false";"";"";"";"";"";""
"SRR502602";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg6h_c-Myc_std";"";1;"SRX150678";NA;"false";"";"";"";"";"";""
"SRR502603";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg6h_c-Myc_std";"";2;"SRX150678";NA;"false";"";"";"";"";"";""
"SRR502604";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_E2F4_UCDavis";"";1;"SRX150679";NA;"false";"";"";"";"";"";""
"SRR502605";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_E2F4_UCDavis";"";2;"SRX150679";NA;"false";"";"";"";"";"";""
"SRR502606";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"USC_ChipSeq_K562_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502607";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg30_c-Jun_std";"";1;"SRX150681";NA;"false";"";"";"";"";"";""
"SRR502608";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Yale_ChipSeq_K562_IFNg30_c-Jun_std";"";2;"SRX150681";NA;"false";"";"";"";"";"";""
"SRR502609";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Pol2_IgG-rab";"";1;"SRX150682";NA;"false";"";"";"";"";"";""
"SRR502610";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Pol2_IgG-rab";"";2;"SRX150682";NA;"false";"";"";"";"";"";""
"SRR502611";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Input_IgG-rab";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502612";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_Input_Harvard_Control";"";1;"SRX150684";NA;"false";"";"";"";"";"";""
"SRR502613";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_Input_Harvard_Control";"";2;"SRX150684";NA;"false";"";"";"";"";"";""
"SRR502614";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_Input_Harvard_Control";"";3;"SRX150684";NA;"false";"";"";"";"";"";""
"SRR502615";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_Input_Harvard_Control";"";4;"SRX150684";NA;"false";"";"";"";"";"";""
"SRR502616";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_Input_Harvard_Control";"";5;"SRX150684";NA;"false";"";"";"";"";"";""
"SRR502617";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_Input_Harvard_Control";"";6;"SRX150684";NA;"false";"";"";"";"";"";""
"SRR502618";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_TBP_IgG-rab";"";1;"SRX150685";NA;"false";"";"";"";"";"";""
"SRR502619";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_TBP_IgG-rab";"";2;"SRX150685";NA;"false";"";"";"";"";"";""
"SRR502620";"";"";"SRP007993";"GM08714 -;- lymphoblastoid cell line, Instability of heterochromatin of chromosomes 1, 9, and 16 with variable combined immunodeficiency; dysmorphic facial features, developmental delay, malabsorption, and recurrent infections; see GM08747 Fibroblast; donor subject is a compound heterozygote: one allele has a G>A transition at nucleotide 1807 (1807G>A) of the DNMT3B gene resulting in an Ala to Thr substitution at codon 603 [Ala603Thr (A603T)], the mutation occurring in a region between motifs I and IV within the catalytic domain of DNMT3B; the second allele has a G>A transition within intron 22 located 11 nucleotides 5-prime of the normal splice acceptor site [IVS22AS,G>A,-11] resulting in the generation of a novel splice acceptor site and a 9-bp insertion in the processed RNA. This results in the insertion of 3 amino acids (serine, threonine, and proline) at codon 744 (744ins3). The insertion was within the conserved region of the catalytic domain, which is likely to be disrupted by the insertion of a proline residue. This mutation was de novo. -;- mesoderm";"USC_ChipSeq_GM08714_Input_UCDavis";"";1;"SRX150686";NA;"false";"";"";"";"";"";""
"SRR502621";"";"";"SRP007993";"GM08714 -;- lymphoblastoid cell line, Instability of heterochromatin of chromosomes 1, 9, and 16 with variable combined immunodeficiency; dysmorphic facial features, developmental delay, malabsorption, and recurrent infections; see GM08747 Fibroblast; donor subject is a compound heterozygote: one allele has a G>A transition at nucleotide 1807 (1807G>A) of the DNMT3B gene resulting in an Ala to Thr substitution at codon 603 [Ala603Thr (A603T)], the mutation occurring in a region between motifs I and IV within the catalytic domain of DNMT3B; the second allele has a G>A transition within intron 22 located 11 nucleotides 5-prime of the normal splice acceptor site [IVS22AS,G>A,-11] resulting in the generation of a novel splice acceptor site and a 9-bp insertion in the processed RNA. This results in the insertion of 3 amino acids (serine, threonine, and proline) at codon 744 (744ins3). The insertion was within the conserved region of the catalytic domain, which is likely to be disrupted by the insertion of a proline residue. This mutation was de novo. -;- mesoderm";"USC_ChipSeq_GM08714_Input_UCDavis";"";2;"SRX150686";NA;"false";"";"";"";"";"";""
"SRR502622";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2(phosphoS2)_IgG-mus";"";1;"SRX150687";NA;"false";"";"";"";"";"";""
"SRR502623";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Pol2(phosphoS2)_IgG-mus";"";2;"SRX150687";NA;"false";"";"";"";"";"";""
"SRR502624";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_BRCA1_(A300-000A)_IgG-rab";"";1;"SRX150688";NA;"false";"";"";"";"";"";""
"SRR502625";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_BRCA1_(A300-000A)_IgG-rab";"";2;"SRX150688";NA;"false";"";"";"";"";"";""
"SRR502626";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_MafK_(SC-477)_IgG-rab";"";1;"SRX150689";NA;"false";"";"";"";"";"";""
"SRR502627";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_MafK_(SC-477)_IgG-rab";"";2;"SRX150689";NA;"false";"";"";"";"";"";""
"SRR502628";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_CTCF_(SC-15914)_std";"";1;"SRX150690";NA;"false";"";"";"";"";"";""
"SRR502629";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_CTCF_(SC-15914)_std";"";2;"SRX150690";NA;"false";"";"";"";"";"";""
"SRR502630";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_STAT1_std";"";1;"SRX150691";NA;"false";"";"";"";"";"";""
"SRR502631";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_STAT1_std";"";2;"SRX150691";NA;"false";"";"";"";"";"";""
"SRR502632";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Znf143_(16618-1-AP)_std";"";1;"SRX150692";NA;"false";"";"";"";"";"";""
"SRR502633";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_Znf143_(16618-1-AP)_std";"";2;"SRX150692";NA;"false";"";"";"";"";"";""
"SRR502634";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_c-Jun_IgG-rab";"";1;"SRX150693";NA;"false";"";"";"";"";"";""
"SRR502635";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"Stanford_ChipSeq_H1-hESC_c-Jun_IgG-rab";"";2;"SRX150693";NA;"false";"";"";"";"";"";""
"SRR502636";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_SPT20_std";"";1;"SRX150694";NA;"false";"";"";"";"";"";""
"SRR502637";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_SPT20_std";"";2;"SRX150694";NA;"false";"";"";"";"";"";""
"SRR502638";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_BHLHE40_(NB100-1800)_IgG-rab";"";1;"SRX150695";NA;"false";"";"";"";"";"";""
"SRR502639";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_BHLHE40_(NB100-1800)_IgG-rab";"";2;"SRX150695";NA;"false";"";"";"";"";"";""
"SRR502640";"";"";"SRP007993";"PANC-1 -;- pancreatic carcinoma, (PMID: 1140870) PANC-1 was established from a pancreatic carcinoma, which was extracted via pancreatico-duodenectomy specimen from a 56-year-old Caucasian individual. Malignancy of this cell line was verified via in vitro and in vivo assays. -;- endoderm";"USC_ChipSeq_PANC-1_Input_UCDavis";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502641";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Input_IgG-rab";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502642";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_HNF4A_std";"";1;"SRX150698";NA;"false";"";"";"";"";"";""
"SRR502643";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_HNF4A_std";"";2;"SRX150698";NA;"false";"";"";"";"";"";""
"SRR502644";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_GRp20_std";"";1;"SRX150699";NA;"false";"";"";"";"";"";""
"SRR502645";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_GRp20_std";"";2;"SRX150699";NA;"false";"";"";"";"";"";""
"SRR502646";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_ERRA_std";"";1;"SRX150700";NA;"false";"";"";"";"";"";""
"SRR502647";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_ERRA_std";"";2;"SRX150700";NA;"false";"";"";"";"";"";""
"SRR502648";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_CEBPB_std";"";1;"SRX150701";NA;"false";"";"";"";"";"";""
"SRR502649";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_CEBPB_std";"";2;"SRX150701";NA;"false";"";"";"";"";"";""
"SRR502650";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_PGC1A_std";"";1;"SRX150702";NA;"false";"";"";"";"";"";""
"SRR502651";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_PGC1A_std";"";2;"SRX150702";NA;"false";"";"";"";"";"";""
"SRR502652";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_Rad21_IgG-rab";"";1;"SRX150703";NA;"false";"";"";"";"";"";""
"SRR502653";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_Rad21_IgG-rab";"";2;"SRX150703";NA;"false";"";"";"";"";"";""
"SRR502654";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_TCF7L2_C9B9_(2565)_UCDavis";"";1;"SRX150704";NA;"false";"";"";"";"";"";""
"SRR502655";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"USC_ChipSeq_HeLa-S3_TCF7L2_C9B9_(2565)_UCDavis";"";2;"SRX150704";NA;"false";"";"";"";"";"";""
"SRR502656";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_HSF1_std";"";1;"SRX150705";NA;"false";"";"";"";"";"";""
"SRR502657";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_HSF1_std";"";2;"SRX150705";NA;"false";"";"";"";"";"";""
"SRR502658";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_insulin_SREBP1_std";"";1;"SRX150706";NA;"false";"";"";"";"";"";""
"SRR502659";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_insulin_SREBP1_std";"";2;"SRX150706";NA;"false";"";"";"";"";"";""
"SRR502660";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_insulin_SREBP1_std";"";3;"SRX150706";NA;"false";"";"";"";"";"";""
"SRR502661";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_Pol2_std";"";1;"SRX150707";NA;"false";"";"";"";"";"";""
"SRR502662";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_forskolin_Pol2_std";"";2;"SRX150707";NA;"false";"";"";"";"";"";""
"SRR502663";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_Input_IgG-rab";"";1;"SRX150708";NA;"false";"";"";"";"";"";""
"SRR502664";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_Input_IgG-rab";"";2;"SRX150708";NA;"false";"";"";"";"";"";""
"SRR502665";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_CEBPB_IgG-rab";"";1;"SRX150709";NA;"false";"";"";"";"";"";""
"SRR502666";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_CEBPB_IgG-rab";"";2;"SRX150709";NA;"false";"";"";"";"";"";""
"SRR502667";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Input_IgG-mus";"";1;"SRX150710";NA;"false";"";"";"";"";"";""
"SRR502668";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Input_IgG-mus";"";2;"SRX150710";NA;"false";"";"";"";"";"";""
"SRR502669";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Pol2_IgG-mus";"";1;"SRX150711";NA;"false";"";"";"";"";"";""
"SRR502670";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Pol2_IgG-mus";"";2;"SRX150711";NA;"false";"";"";"";"";"";""
"SRR502671";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Brg1_IgG-mus";"";1;"SRX150712";NA;"false";"";"";"";"";"";""
"SRR502672";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Brg1_IgG-mus";"";2;"SRX150712";NA;"false";"";"";"";"";"";""
"SRR502673";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Ini1_IgG-mus";"";1;"SRX150713";NA;"false";"";"";"";"";"";""
"SRR502674";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Ini1_IgG-mus";"";2;"SRX150713";NA;"false";"";"";"";"";"";""
"SRR502675";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Ini1_IgG-mus";"";1;"SRX150714";NA;"false";"";"";"";"";"";""
"SRR502676";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Ini1_IgG-mus";"";2;"SRX150714";NA;"false";"";"";"";"";"";""
"SRR502677";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Ini1_IgG-mus";"";3;"SRX150714";NA;"false";"";"";"";"";"";""
"SRR502678";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Nrf1_IgG-mus";"";1;"SRX150715";NA;"false";"";"";"";"";"";""
"SRR502679";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_Nrf1_IgG-mus";"";2;"SRX150715";NA;"false";"";"";"";"";"";""
"SRR502680";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_BAF155_IgG-mus";"";1;"SRX150716";NA;"false";"";"";"";"";"";""
"SRR502681";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_BAF155_IgG-mus";"";2;"SRX150716";NA;"false";"";"";"";"";"";""
"SRR502682";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_BAF155_IgG-mus";"";3;"SRX150716";NA;"false";"";"";"";"";"";""
"SRR502683";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_BAF170_IgG-mus";"";1;"SRX150717";NA;"false";"";"";"";"";"";""
"SRR502684";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_BAF170_IgG-mus";"";2;"SRX150717";NA;"false";"";"";"";"";"";""
"SRR502685";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_BAF170_IgG-mus";"";3;"SRX150717";NA;"false";"";"";"";"";"";""
"SRR502686";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_Input_IgG-mus";"";1;"SRX150718";NA;"false";"";"";"";"";"";""
"SRR502687";"";"";"SRP007993";"GM10847 -;- lymphoblastoid, International HapMap Project, CEPH/Utah, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM10847_Input_IgG-mus";"";2;"SRX150718";NA;"false";"";"";"";"";"";""
"SRR502688";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_Pol2_IgG-mus";"";1;"SRX150719";NA;"false";"";"";"";"";"";""
"SRR502689";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_Pol2_IgG-mus";"";2;"SRX150719";NA;"false";"";"";"";"";"";""
"SRR502690";"";"";"SRP007993";"GM12892 -;- B-lymphocyte, lymphoblastoid, International HapMap Project, CEPH/Utah pedigree 1463, treatment: Epstein-Barr Virus transformed -;- mesoderm";"Stanford_ChipSeq_GM12892_Pol2_IgG-mus";"";3;"SRX150719";NA;"false";"";"";"";"";"";""
"SRR502691";"";"";"SRP007993";"MCF10A-Er-Src -;- mammary gland, non-tumorigenic epithelial, inducible cell line, derived from the MCF-10A parental cells and contain ER-Src, a derivative of the Src kinase oncoprotein (v-Src) that is fused to the ligand-binding domain of the estrogen receptor (ER) -;- ectoderm";"Harvard_ChipSeq_MCF10A-Er-Src_Input_std";"";1;NA;NA;"false";"";"";"";"";"";""
"SRR502692";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_UBTF_(SAB1404509)_IgG-mus";"";1;"SRX150721";NA;"false";"";"";"";"";"";""
"SRR502693";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_UBTF_(SAB1404509)_IgG-mus";"";2;"SRX150721";NA;"false";"";"";"";"";"";""
"SRR502694";"";"";"SRP007993";"NB4 -;- acute promyelocytic leukemia cell line. (PMID: 1995093) -;- mesoderm";"Stanford_ChipSeq_NB4_c-Myc_std";"";1;"SRX150722";NA;"false";"";"";"";"";"";""
"SRR502695";"";"";"SRP007993";"NB4 -;- acute promyelocytic leukemia cell line. (PMID: 1995093) -;- mesoderm";"Stanford_ChipSeq_NB4_c-Myc_std";"";2;"SRX150722";NA;"false";"";"";"";"";"";""
"SRR502696";"";"";"SRP007993";"NB4 -;- acute promyelocytic leukemia cell line. (PMID: 1995093) -;- mesoderm";"Stanford_ChipSeq_NB4_Max_std";"";1;"SRX150723";NA;"false";"";"";"";"";"";""
"SRR502697";"";"";"SRP007993";"NB4 -;- acute promyelocytic leukemia cell line. (PMID: 1995093) -;- mesoderm";"Stanford_ChipSeq_NB4_Max_std";"";2;"SRX150723";NA;"false";"";"";"";"";"";""
"SRR502698";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Pol2(phosphoS2)_std";"";1;"SRX150724";NA;"false";"";"";"";"";"";""
"SRR502699";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_Pol2(phosphoS2)_std";"";2;"SRX150724";NA;"false";"";"";"";"";"";""
"SRR502700";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_USF2_IgG-rab";"";1;"SRX150725";NA;"false";"";"";"";"";"";""
"SRR502701";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_USF2_IgG-rab";"";2;"SRX150725";NA;"false";"";"";"";"";"";""
"SRR502702";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Rad21_IgG-rab";"";1;"SRX150726";NA;"false";"";"";"";"";"";""
"SRR502703";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Rad21_IgG-rab";"";2;"SRX150726";NA;"false";"";"";"";"";"";""
"SRR502704";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Nrf1_IgG-rab";"";1;"SRX150727";NA;"false";"";"";"";"";"";""
"SRR502705";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_Nrf1_IgG-rab";"";2;"SRX150727";NA;"false";"";"";"";"";"";""
"SRR502706";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_JunD_IgG-rab";"";1;"SRX150728";NA;"false";"";"";"";"";"";""
"SRR502707";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_JunD_IgG-rab";"";2;"SRX150728";NA;"false";"";"";"";"";"";""
"SRR502708";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_IRF3_IgG-rab";"";1;"SRX150729";NA;"false";"";"";"";"";"";""
"SRR502709";"";"";"SRP007993";"HepG2 -;- hepatocellular carcinoma -;- endoderm";"Stanford_ChipSeq_HepG2_IRF3_IgG-rab";"";2;"SRX150729";NA;"false";"";"";"";"";"";""
"SRR502710";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_IRF3_IgG-mus";"";1;"SRX150730";NA;"false";"";"";"";"";"";""
"SRR502711";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_IRF3_IgG-mus";"";2;"SRX150730";NA;"false";"";"";"";"";"";""
"SRR502712";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_NF-E2_(SC-22827)_std";"";1;"SRX150731";NA;"false";"";"";"";"";"";""
"SRR502713";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_NF-E2_(SC-22827)_std";"";2;"SRX150731";NA;"false";"";"";"";"";"";""
"SRR502714";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TBLR1_(ab24550)_IgG-mus";"";1;"SRX150732";NA;"false";"";"";"";"";"";""
"SRR502715";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_TBLR1_(ab24550)_IgG-mus";"";2;"SRX150732";NA;"false";"";"";"";"";"";""
"SRR568121";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_ZNF384_(HPA004051)_IgG-mus";"";1;"SRX186607";NA;"false";"";"";"";"";"";""
"SRR568122";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_ZNF384_(HPA004051)_IgG-mus";"";2;"SRX186607";NA;"false";"";"";"";"";"";""
"SRR568123";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_SREBP2_IgG-rab";"";1;"SRX186608";NA;"false";"";"";"";"";"";""
"SRR568124";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_SREBP2_IgG-rab";"";2;"SRX186608";NA;"false";"";"";"";"";"";""
"SRR568125";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_CDP_(sc-6327)_IgG-mus";"";1;"SRX186609";NA;"false";"";"";"";"";"";""
"SRR568126";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_CDP_(sc-6327)_IgG-mus";"";2;"SRX186609";NA;"false";"";"";"";"";"";""
"SRR568127";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_ERRA_IgG-rab";"";1;"SRX186610";NA;"false";"";"";"";"";"";""
"SRR568128";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_ERRA_IgG-rab";"";2;"SRX186610";NA;"false";"";"";"";"";"";""
"SRR568129";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_CTCF_(SC-15914)_IgG-rab";"";1;"SRX186611";NA;"false";"";"";"";"";"";""
"SRR568130";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_CTCF_(SC-15914)_IgG-rab";"";2;"SRX186611";NA;"false";"";"";"";"";"";""
"SRR568131";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_c-Myc_IgG-rab";"";1;"SRX186612";NA;"false";"";"";"";"";"";""
"SRR568132";"";"";"SRP007993";"A549 -;- epithelial cell line derived from a lung carcinoma tissue. (PMID: 175022), \"This line was initiated in 1972 by D.J. Giard, et al. through explant culture of lung carcinomatous tissue from a 58-year-old caucasian male.\" - ATCC, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_A549_c-Myc_IgG-rab";"";2;"SRX186612";NA;"false";"";"";"";"";"";""
"SRR568133";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_GATA1_(SC-266)_IgG-mus";"";1;"SRX186613";NA;"false";"";"";"";"";"";""
"SRR568134";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_GATA1_(SC-266)_IgG-mus";"";2;"SRX186613";NA;"false";"";"";"";"";"";""
"SRR568135";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_c-Jun_IgG-rab";"";1;"SRX186614";NA;"false";"";"";"";"";"";""
"SRR568136";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_c-Jun_IgG-rab";"";2;"SRX186614";NA;"false";"";"";"";"";"";""
"SRR568137";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ZC3H11A_(NB100-74650)_IgG-rab";"";1;"SRX186615";NA;"false";"";"";"";"";"";""
"SRR568138";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ZC3H11A_(NB100-74650)_IgG-rab";"";2;"SRX186615";NA;"false";"";"";"";"";"";""
"SRR568139";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ZNF-MIZD-CP1_(ab65767)_IgG-rab";"";1;"SRX186616";NA;"false";"";"";"";"";"";""
"SRR568140";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ZNF-MIZD-CP1_(ab65767)_IgG-rab";"";2;"SRX186616";NA;"false";"";"";"";"";"";""
"SRR568141";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_COREST_(sc-30189)_IgG-rab";"";1;"SRX186617";NA;"false";"";"";"";"";"";""
"SRR568142";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_COREST_(sc-30189)_IgG-rab";"";2;"SRX186617";NA;"false";"";"";"";"";"";""
"SRR568143";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_MAZ_(ab85725)_IgG-rab";"";1;"SRX186618";NA;"false";"";"";"";"";"";""
"SRR568144";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_MAZ_(ab85725)_IgG-rab";"";2;"SRX186618";NA;"false";"";"";"";"";"";""
"SRR568145";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_Mxi1_(AF4185)_IgG-rab";"";1;"SRX186619";NA;"false";"";"";"";"";"";""
"SRR568146";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_Mxi1_(AF4185)_IgG-rab";"";2;"SRX186619";NA;"false";"";"";"";"";"";""
"SRR568147";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_RFX5_(200-401-194)_IgG-rab";"";1;"SRX186620";NA;"false";"";"";"";"";"";""
"SRR568148";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_RFX5_(200-401-194)_IgG-rab";"";2;"SRX186620";NA;"false";"";"";"";"";"";""
"SRR568149";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_MafK_(ab50322)_IgG-mus";"";1;"SRX186621";NA;"false";"";"";"";"";"";""
"SRR568150";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_MafK_(ab50322)_IgG-mus";"";2;"SRX186621";NA;"false";"";"";"";"";"";""
"SRR568151";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_SREBP1_IgG-rab";"";1;"SRX186622";NA;"false";"";"";"";"";"";""
"SRR568152";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_SREBP1_IgG-rab";"";2;"SRX186622";NA;"false";"";"";"";"";"";""
"SRR568153";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_HCFC1_(NB100-68209)_IgG-rab";"";1;"SRX186623";NA;"false";"";"";"";"";"";""
"SRR568154";"";"";"SRP007993";"HeLa-S3 -;- cervical carcinoma -;- ectoderm";"Stanford_ChipSeq_HeLa-S3_HCFC1_(NB100-68209)_IgG-rab";"";2;"SRX186623";NA;"false";"";"";"";"";"";""
"SRR568155";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_ZNF274_(M01)_UCDavis";"";1;"SRX186624";NA;"false";"";"";"";"";"";""
"SRR568156";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_ZNF274_(M01)_UCDavis";"";2;"SRX186624";NA;"false";"";"";"";"";"";""
"SRR568157";"";"";"SRP007993";"H1-hESC -;- embryonic stem cells -;- inner cell mass";"USC_ChipSeq_H1-hESC_ZNF274_(M01)_UCDavis";"";3;"SRX186624";NA;"false";"";"";"";"";"";""
"SRR568158";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ELK1_(1277-1)_IgG-rab";"";1;"SRX186625";NA;"false";"";"";"";"";"";""
"SRR568159";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ELK1_(1277-1)_IgG-rab";"";2;"SRX186625";NA;"false";"";"";"";"";"";""
"SRR568160";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ZNF384_(HPA004051)_IgG-rab";"";1;"SRX186626";NA;"false";"";"";"";"";"";""
"SRR568161";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_ZNF384_(HPA004051)_IgG-rab";"";2;"SRX186626";NA;"false";"";"";"";"";"";""
"SRR568162";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_CDP_(sc-6327)_IgG-rab";"";1;"SRX186627";NA;"false";"";"";"";"";"";""
"SRR568163";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_CDP_(sc-6327)_IgG-rab";"";2;"SRX186627";NA;"false";"";"";"";"";"";""
"SRR568164";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_CHD1_(NB100-60411)_IgG-rab";"";1;"SRX186628";NA;"false";"";"";"";"";"";""
"SRR568165";"";"";"SRP007993";"IMR90 -;- fetal lung fibroblasts, newly promoted to tier 2: not in 2011 analysis -;- endoderm";"Stanford_ChipSeq_IMR90_CHD1_(NB100-60411)_IgG-rab";"";2;"SRX186628";NA;"false";"";"";"";"";"";""
"SRR568166";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_Input_IgG-rab";"";1;"SRX186629";NA;"false";"";"";"";"";"";""
"SRR568167";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_Input_IgG-rab";"";2;"SRX186629";NA;"false";"";"";"";"";"";""
"SRR568168";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_HCFC1_(NB100-68209)_IgG-rab";"";1;"SRX186630";NA;"false";"";"";"";"";"";""
"SRR568169";"";"";"SRP007993";"K562 -;- leukemia, \"The continuous cell line K-562 was established by Lozzio and Lozzio from the pleural effusion of a 53-year-old female with chronic myelogenous leukemia in terminal blast crises.\" - ATCC -;- mesoderm";"Stanford_ChipSeq_K562_HCFC1_(NB100-68209)_IgG-rab";"";2;"SRX186630";NA;"false";"";"";"";"";"";""
"SRR568170";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_p300_(SC-584)_IgG-rab";"";1;"SRX186631";NA;"false";"";"";"";"";"";""
"SRR568171";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_p300_(SC-584)_IgG-rab";"";2;"SRX186631";NA;"false";"";"";"";"";"";""
"SRR568172";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_SMC3_(ab9263)_IgG-rab";"";1;"SRX186632";NA;"false";"";"";"";"";"";""
"SRR568173";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_SMC3_(ab9263)_IgG-rab";"";2;"SRX186632";NA;"false";"";"";"";"";"";""
"SRR568174";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_Rad21_IgG-rab";"";1;"SRX186633";NA;"false";"";"";"";"";"";""
"SRR568175";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_Rad21_IgG-rab";"";2;"SRX186633";NA;"false";"";"";"";"";"";""
"SRR568176";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_RFX5_(200-401-194)_IgG-rab";"";1;"SRX186634";NA;"false";"";"";"";"";"";""
"SRR568177";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_RFX5_(200-401-194)_IgG-rab";"";2;"SRX186634";NA;"false";"";"";"";"";"";""
"SRR568178";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_Nrf1_IgG-rab";"";1;"SRX186635";NA;"false";"";"";"";"";"";""
"SRR568179";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_Nrf1_IgG-rab";"";2;"SRX186635";NA;"false";"";"";"";"";"";""
"SRR568180";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_Mxi1_(AF4185)_IgG-rab";"";1;"SRX186636";NA;"false";"";"";"";"";"";""
"SRR568181";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_Mxi1_(AF4185)_IgG-rab";"";2;"SRX186636";NA;"false";"";"";"";"";"";""
"SRR568182";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_JunD_IgG-rab";"";1;"SRX186637";NA;"false";"";"";"";"";"";""
"SRR568183";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_JunD_IgG-rab";"";2;"SRX186637";NA;"false";"";"";"";"";"";""
"SRR568184";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_CTCF_(SC-15914)_IgG-rab";"";1;"SRX186638";NA;"false";"";"";"";"";"";""
"SRR568185";"";"";"SRP007993";"SK-N-SH -;- neuroblastoma, newly promoted to tier 2: not in 2011 analysis, the SK-N-SH line was established from a neuroblastoma in a 4 year old individual. -;- ectoderm";"Stanford_ChipSeq_SK-N-SH_CTCF_(SC-15914)_IgG-rab";"";2;"SRX186638";NA;"false";"";"";"";"";"";""
"SRR568186";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_JunD_IgG-rab";"";1;"SRX186639";NA;"false";"";"";"";"";"";""
"SRR568187";"";"";"SRP007993";"GM12878 -;- B-lymphocyte, lymphoblastoid, International HapMap Project - CEPH/Utah - European Caucasion, Epstein-Barr Virus -;- mesoderm";"Stanford_ChipSeq_GM12878_JunD_IgG-rab";"";2;"SRX186639";NA;"false";"";"";"";"";"";""
